Data / Research funding / Lymphatic Research
Lymphatic Research: 1,238 NIH awards ($1.4B) to 244 organizations
1,238 NIH awards ($1.4B) in the NIH spending category Lymphatic Research, to 244 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 1,238 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $29,642,385 | September 12, 1997 | November 30, 2025 | RATHMELL, WENDY KIMRYN | reporter.nih.gov |
| MANUFACTURE OF CLINICAL GRADE EPSTEIN-BARR VIRUS VACCINE | NIH | National Cancer Institute | 2023 to 2025 | $22,579,077 | September 22, 2025 | September 21, 2027 | reporter.nih.gov | |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $20,980,807 | December 1, 1996 | February 28, 2029 | MAITRA, ANIRBAN | reporter.nih.gov |
| The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study | NIH | National Cancer Institute | 2021 to 2025 | $10,080,862 | June 23, 2015 | March 31, 2026 | CERHAN, JAMES R | reporter.nih.gov |
| The 10,000 Families Cohort: a new study to understand the environmental causes of cancer | NIH | National Cancer Institute | 2023 to 2025 | $6,827,634 | September 24, 2021 | August 31, 2028 | POYNTER, JENNY N. | reporter.nih.gov |
| Washington University/Siteman Cancer Center Lead Academic Site | NIH | National Cancer Institute | 2021 to 2025 | $6,572,668 | March 5, 2019 | February 28, 2026 | BARTLETT, NANCY L | reporter.nih.gov |
| Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). | NIH | National Cancer Institute | 2021 to 2025 | $6,371,380 | September 1, 2021 | June 30, 2027 | BROOKS, DAVID G | reporter.nih.gov |
| Metabolic gatekeepers in B-cell malignancies | NIH | National Cancer Institute | 2021 to 2025 | $5,936,594 | April 1, 2016 | August 31, 2028 | MÜSCHEN, MARKUS | reporter.nih.gov |
| Multi-scale Spatial Mapping of Human Lymphatic Vessels | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $5,779,437 | August 1, 2022 | June 30, 2027 | SINGHAL, DHRUV | reporter.nih.gov |
| Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA) | NIH | National Cancer Institute | 2024 to 2025 | $5,130,804 | September 1, 2024 | August 31, 2029 | FAN, RONG | reporter.nih.gov |
| Towards targeting the lymphoma microenvironment | NIH | National Cancer Institute | 2021 to 2025 | $5,082,235 | September 1, 2020 | August 31, 2027 | WENDEL, HANS-GUIDO | reporter.nih.gov |
| From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $4,812,450 | September 12, 2023 | July 31, 2030 | DALLA-FAVERA, RICCARDO | reporter.nih.gov |
| Brain fluid clearance and misfolded protein dynamics following traumatic brain injury | NIH | National Institute on Aging | 2023 to 2025 | $4,618,282 | September 30, 2023 | June 30, 2029 | BUTLER, TRACY A. | reporter.nih.gov |
| The genetic and epigenetic etiology of progression from the precursor state to chronic lymphocytic leukemia (CLL) | NIH | National Cancer Institute | 2022 to 2025 | $4,109,575 | September 8, 2022 | August 31, 2027 | SLAGER, SUSAN L | reporter.nih.gov |
| Targeting Epigenetic Circuits in B-Cell Lymphomas | NIH | National Cancer Institute | 2021 to 2024 | $3,926,225 | September 13, 2018 | August 31, 2025 | MELNICK, ARI M. | reporter.nih.gov |
| Defining the Role of Post-TBI Sleep Disruption in the Development of CTE and Alzheimer's Disease-Related Neuropathology | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $3,859,922 | September 20, 2022 | August 31, 2025 | PESKIND, ELAINE R. | reporter.nih.gov |
| Defining the lymphatic basis of protein losing enteropathy after Fontan palliation or inflammatory gut disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,759,375 | September 30, 2021 | June 30, 2027 | RANDOLPH, GWENDALYN J | reporter.nih.gov |
| Social genomic mechanisms of health disparities among Adolescent and Young Adult (AYA) cancer survivors | NIH | National Cancer Institute | 2021 to 2025 | $3,743,381 | September 10, 2021 | August 31, 2027 | ZEBRACK, BRADLEY JAY | reporter.nih.gov |
| Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic | NIH | National Cancer Institute | 2021 to 2025 | $3,727,726 | September 25, 2001 | June 30, 2026 | WEROHA, SARAVUT | reporter.nih.gov |
| Lymphatics-Glymphatics in CNS Fluid Homeostasis | NIH | National Center for Complementary & Integrative Health | 2021 to 2025 | $3,644,017 | April 1, 2021 | March 31, 2026 | BENVENISTE, HELENE D | reporter.nih.gov |
| Effects of CSF1R Blockade on Repopulation of SIV Reservoirs from the CNS to the Periphery After Antiretroviral Therapy Interruption | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,573,272 | July 15, 2021 | June 30, 2027 | WILLIAMS, KENNETH C | reporter.nih.gov |
| Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma | NIH | National Cancer Institute | 2021 to 2023 | $3,557,045 | May 1, 2021 | April 30, 2024 | NIXON, DOUGLAS F | reporter.nih.gov |
| Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers | NIH | National Cancer Institute | 2021 to 2024 | $3,536,890 | April 1, 2020 | September 30, 2025 | AMBINDER, RICHARD FREDERICK | reporter.nih.gov |
| Advanced MRI studies of cerebrovascular and lymphatic abnormalities in LRRK2 mouse models of Parkinson's disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,536,285 | April 1, 2021 | March 31, 2027 | SMITH, WANLI W | reporter.nih.gov |
| Molecular Mechanisms Controlling Lymphatic Vascular Function in Health and Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,522,987 | July 5, 2016 | May 31, 2027 | CHEN, HONG | reporter.nih.gov |
| Mosaic: post-zygotic mutations in vascular malformations | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,511,307 | February 8, 2016 | June 30, 2025 | BENNETT, JAMES T | reporter.nih.gov |
| Does VECAD at Schlemm canal cell-junctions determine IOP and glaucoma risk? | NIH | National Eye Institute | 2021 to 2025 | $3,499,675 | January 1, 2021 | November 30, 2025 | JOHN, SIMON W | reporter.nih.gov |
| Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells | NIH | National Cancer Institute | 2021 to 2025 | $3,469,484 | January 7, 2021 | December 31, 2025 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| The MYC Transcription Factor Network and the Path to Cancer | NIH | National Cancer Institute | 2021 to 2024 | $3,449,610 | September 1, 2018 | August 31, 2025 | EISENMAN, ROBERT NEIL | reporter.nih.gov |
| A Vaccine for Lymphatic Filariasis, LFGuard™ | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,448,456 | March 1, 2019 | November 30, 2027 | CARTER, DARRICK ALBERT | reporter.nih.gov |
| B cell determinants of EBV latency (supplement) | NIH | National Cancer Institute | 2022 to 2025 | $3,376,443 | September 9, 2022 | August 31, 2027 | CESARMAN, ETHEL | reporter.nih.gov |
| Germline and Somatic Genomic Studies in CLL | NIH | National Cancer Institute | 2021 to 2025 | $3,266,846 | July 1, 2021 | September 30, 2026 | SLAGER, SUSAN L | reporter.nih.gov |
| Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients | NIH | National Cancer Institute | 2021 to 2025 | $3,235,983 | July 1, 2020 | June 30, 2027 | LAROCCA, CECILIA | reporter.nih.gov |
| Protecting colonic mucus to mitigate acute intestinal graft-versus-host disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,218,917 | August 15, 2015 | June 30, 2026 | JENQ, ROBERT | reporter.nih.gov |
| Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $3,211,729 | March 4, 2021 | February 28, 2026 | ALIZADEH, ASH ARASH | reporter.nih.gov |
| Pre-malignant mutation landscape and risk factors for progression to hematologic cancers | NIH | National Cancer Institute | 2021 to 2025 | $3,207,103 | April 1, 2021 | March 31, 2027 | DESAI, PINKAL | reporter.nih.gov |
| Outcomes for CLL patients treated with novel therapy | NIH | National Cancer Institute | 2021 to 2025 | $3,205,518 | September 15, 2021 | August 31, 2026 | KAY, NEIL E | reporter.nih.gov |
| Pacritinib in rel/refr T-cell lymphomas | NIH | National Cancer Institute | 2021 to 2025 | $3,194,893 | September 1, 2021 | August 31, 2027 | WILCOX, RYAN A | reporter.nih.gov |
| Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL) | NIH | National Cancer Institute | 2021 to 2025 | $3,143,480 | April 1, 2021 | March 31, 2027 | BROWN, JENNIFER R | reporter.nih.gov |
| TYK2 Fusions in Lymphoma | NIH | National Cancer Institute | 2025 | $3,111,184 | September 1, 2025 | August 31, 2029 | ELENITOBA-JOHNSON, KOJO S. J. | reporter.nih.gov |
| Epstein Barr Virus Driven Mechanisms of Post Transplant Lymphoproliferative Disease | NIH | National Cancer Institute | 2023 to 2025 | $3,096,663 | September 1, 2023 | August 31, 2028 | MARTINEZ, OLIVIA M | reporter.nih.gov |
| Leveraging canine spontaneous cancer to optimize the power of blood biopsy | NIH | National Cancer Institute | 2021 to 2025 | $3,095,555 | June 7, 2021 | May 31, 2027 | KARLSSON, ELINOR | reporter.nih.gov |
| The glymphatic system at the crossroad of integrative health approaches inchronic pain | NIH | National Center for Complementary & Integrative Health | 2021 to 2025 | $3,067,927 | August 1, 2021 | May 31, 2026 | NEDERGAARD, MAIKEN | reporter.nih.gov |
| Efflux Route Responses of Cerebral Waste Clearance During Progression of Alzheimer’s Disease | NIH | National Institute on Aging | 2025 | $3,062,355 | September 15, 2025 | August 31, 2029 | JIANG, QUAN | reporter.nih.gov |
| Noninvasive sensory stimulation to promote glymphatic-lymphatic clearance for the treatment of Alzheimer’s Disease | NIH | National Center for Complementary & Integrative Health | 2021 to 2025 | $3,032,391 | May 15, 2021 | April 30, 2026 | TSAI, LI-HUEI | reporter.nih.gov |
| Quantitative assessment of pre-metastatic immune subversion as a risk factor for melanoma relapse | NIH | National Cancer Institute | 2022 to 2025 | $3,027,575 | September 1, 2022 | August 31, 2027 | MARKOVIC, SVETOMIR NENAD | reporter.nih.gov |
| Mitochondrial respiration as a regulator of lymphatic cell fate and therapeutic lymphangiogenesis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,026,108 | July 1, 2022 | June 30, 2027 | OLIVER, GUILLERMO C | reporter.nih.gov |
| Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV | NIH | National Cancer Institute | 2022 to 2025 | $3,019,287 | September 12, 2022 | August 31, 2027 | BHADURI-MCINTOSH, SUMITA | reporter.nih.gov |
| Cbfb in RORgt-regulated T cell function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,010,210 | May 1, 2014 | May 31, 2029 | SUN, ZUOMING | reporter.nih.gov |
| Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,996,021 | June 1, 2011 | January 31, 2027 | WU, CATHERINE JU-YING | reporter.nih.gov |
| Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids | NIH | National Institute on Aging | 2022 to 2025 | $2,986,919 | September 1, 2022 | May 31, 2027 | WANG, YANLING | reporter.nih.gov |
| Discovery and Characterization of Genetic Risk Loci in Sjogren's Syndrome | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $2,957,132 | September 7, 2020 | August 31, 2025 | LESSARD, CHRISTOPHER J | reporter.nih.gov |
| Functions and mechanisms of transcriptional coactivator OCA-B in B cell development and lymphomagenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,950,108 | December 12, 2019 | November 30, 2025 | ROEDER, ROBERT G | reporter.nih.gov |
| Modeling Multi-Source Data in Hodgkin Lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,935,832 | March 1, 2022 | February 28, 2027 | PARSONS, SUSAN KENYON | reporter.nih.gov |
| Personalized Risk Prediction to Reduce Cardiovascular Disease in Childhood Cancer Survivors | NIH | National Cancer Institute | 2022 to 2025 | $2,933,453 | July 15, 2022 | April 30, 2027 | HOWELL, REBECCA MAUREEN | reporter.nih.gov |
| Molecular Mechanisms of Drug Resistance in Primary Brain Tumors | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,926,627 | January 1, 2018 | November 30, 2025 | MELLINGHOFF, INGO K | reporter.nih.gov |
| Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines | NIH | National Cancer Institute | 2022 to 2025 | $2,917,317 | December 9, 2021 | November 30, 2026 | KENDERIAN, SAAD J. | reporter.nih.gov |
| The synergistic contributions of EBV and malaria to the etiology of Burkitt lymphoma | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,895,508 | December 12, 2019 | January 31, 2025 | SAMAYOA REYES, GABRIELA M | reporter.nih.gov |
| Epigenetic regulation of lymphatic development | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,845,228 | May 1, 2018 | June 30, 2026 | TRIVEDI, CHINMAY M | reporter.nih.gov |
| Effects of Resonance-Frequency Breathing on Preclinical Alzheimer’s Disease Biomarkers and Cognition | NIH | National Institute on Aging | 2023 to 2025 | $2,839,330 | January 15, 2023 | December 31, 2027 | MATHER, MARA | reporter.nih.gov |
| Altered Lymphatic Function and Development in Congenital Heart Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,838,877 | June 1, 2016 | May 31, 2027 | DATAR, SANJEEV A. | reporter.nih.gov |
| Mechanism of microbiota-mediated potentiation of checkpoint blockade efficacy in lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,809,344 | August 1, 2021 | July 31, 2026 | LITTMAN, DAN | reporter.nih.gov |
| anti-miR-10b Nanodrug for Treatment of Breast Cancer Metastasis: Study in Companion Animals | NIH | National Cancer Institute | 2021 to 2025 | $2,789,961 | July 13, 2021 | June 30, 2027 | MOORE, ANNA | reporter.nih.gov |
| Investigate the role of extracellular vesicles in promoting the progression of pulmonary lymphangioleiomyomatosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,784,762 | December 20, 2021 | November 30, 2026 | KARBOWNICZEK, MAGDALENA | reporter.nih.gov |
| Minimally invasive access and aspiration of circulating lymphocytes from the thoracic duct | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,773,831 | September 23, 2016 | May 31, 2026 | CALLAGHAN, MATTHEW | reporter.nih.gov |
| A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity | NIH | National Cancer Institute | 2022 to 2025 | $2,770,577 | February 24, 2022 | January 31, 2027 | DIEFENBACH, CATHERINE SIBYL | reporter.nih.gov |
| Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison | NIH | National Cancer Institute | 2022 to 2025 | $2,766,745 | July 1, 2022 | June 30, 2027 | JIM, HEATHER S.L. | reporter.nih.gov |
| Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy | NIH | National Cancer Institute | 2023 to 2025 | $2,766,158 | September 1, 2023 | August 31, 2028 | HILL, JOSHUA AIDEN | reporter.nih.gov |
| Probing cellular, molecular and biomechanical barriers to immunotherapy in the tumor microenvironment with organotypic in vitro models of the tumor-lympho-immune interface | NIH | National Cancer Institute | 2021 to 2025 | $2,759,610 | August 1, 2021 | July 31, 2027 | SWARTZ, MELODY ANN | reporter.nih.gov |
| Regulation of anti-tumor immunity by HDAC11 | NIH | National Cancer Institute | 2021 to 2024 | $2,757,378 | June 1, 2020 | May 31, 2026 | SETO, EDWARD | reporter.nih.gov |
| Tissue Resident memory T cell responses to cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,755,604 | February 12, 2018 | June 30, 2028 | TURK, MARY JO | reporter.nih.gov |
| Rhesus HHV-8 homologue in AIDS-related malignancies | NIH | National Cancer Institute | 2021 to 2024 | $2,752,636 | July 1, 1997 | July 31, 2025 | WONG, SCOTT W | reporter.nih.gov |
| Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel | NIH | National Cancer Institute | 2021 to 2024 | $2,726,050 | September 1, 2020 | May 31, 2025 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies | NIH | National Cancer Institute | 2021 to 2024 | $2,720,622 | July 1, 2020 | June 30, 2025 | WANG, JIN | reporter.nih.gov |
| BAF complex deregulation in lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,711,912 | August 2, 2022 | July 31, 2027 | GREEN, MICHAEL RICHARD | reporter.nih.gov |
| New roles of endothelial regrowth in ischemic tissue recovery and regeneration | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,697,119 | April 1, 2022 | March 31, 2027 | KUME, TSUTOMU | reporter.nih.gov |
| Spatially resolved, single cell biomarkers of B cell lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,690,152 | August 1, 2022 | July 31, 2027 | MERCHANT, AKIL | reporter.nih.gov |
| InterLymph Consortium: interrogating pleiotropy and gene by environment interactions among hematopoietic malignancies. | NIH | National Cancer Institute | 2021 to 2025 | $2,685,053 | September 3, 2021 | August 31, 2026 | MCKAY, JAMES DOWLING | reporter.nih.gov |
| Study of Activity-Dependent Sympathetic Sprouting | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,675,718 | May 4, 2004 | June 30, 2026 | ZHANG, JUN-MING | reporter.nih.gov |
| Immune system supports brain function | NIH | National Institute on Aging | 2021 to 2025 | $2,673,906 | May 1, 2010 | May 31, 2030 | KIPNIS, JONATHAN | reporter.nih.gov |
| BAFF-R CAR T cell therapy for ALL | NIH | National Cancer Institute | 2022 to 2025 | $2,663,058 | April 18, 2022 | March 31, 2027 | WANG, XIULI | reporter.nih.gov |
| The Molecular and Genetic Pathogenesis of LAM | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,660,652 | September 21, 2016 | February 28, 2026 | HENSKE, ELIZABETH P | reporter.nih.gov |
| Genetic and Biochemical Studies of KSHV LANA | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,646,919 | April 1, 2020 | March 31, 2026 | KAYE, KENNETH M | reporter.nih.gov |
| Supplement: Stalled capillary flow affects protein clearance by modulating interstitial fluid flow | NIH | National Institute on Aging | 2021 to 2022 | $2,646,437 | May 15, 2015 | April 30, 2024 | SCHAFFER, CHRIS B | reporter.nih.gov |
| Targeting Lymph Node Dependent Immune Tolerance in Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,643,851 | April 1, 2021 | March 31, 2026 | ENGLEMAN, EDGAR G. | reporter.nih.gov |
| Targeted Therapies for Lymphoid Malignancies | NIH | National Cancer Institute | 2021 to 2025 | $2,642,763 | April 1, 2013 | January 31, 2026 | WOYACH, JENNIFER A. | reporter.nih.gov |
| Tumor suppressor reprogramming by EBV through post-translational modification | NIH | National Cancer Institute | 2022 to 2025 | $2,640,070 | September 1, 2022 | August 31, 2028 | ROBERTSON, ERLE S. | reporter.nih.gov |
| Lymphatic regulation of lymph node function in lupus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,639,789 | February 1, 2010 | January 31, 2028 | LU, THERESA T. | reporter.nih.gov |
| VEGFR Signaling Controls Lymphatic Junctions | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,637,007 | July 1, 2022 | June 30, 2027 | SCALLAN, JOSHUA PAUL | reporter.nih.gov |
| Translation of a novel combination therapy approach for non-Hodgkin lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,620,855 | September 1, 2022 | August 31, 2027 | NAIK, SHRUTHI | reporter.nih.gov |
| Essential role of the cyclin-G associated kinase (GAK) in diffuse large B-cell lymphoma progression | NIH | National Cancer Institute | 2025 | $2,617,975 | August 1, 2025 | July 31, 2029 | SCHATZ, JONATHAN H | reporter.nih.gov |
| Targeting Latency Switch in EBV+ Lymphomas | NIH | National Cancer Institute | 2022 to 2025 | $2,611,281 | July 1, 2022 | June 30, 2027 | ROTH, LISA GIULINO | reporter.nih.gov |
| Human 3D Neuro-Vascular Interaction and Meningeal Lymphatic Models with Application to Alzheimer’s Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,593,927 | May 1, 2021 | April 30, 2026 | KAMM, ROGER D | reporter.nih.gov |
| Depleting S1P to reverse immune exclusion for effective cancer immunotherapy | NIH | National Cancer Institute | 2025 | $2,592,085 | August 1, 2025 | July 31, 2029 | STONE, EVERETT | reporter.nih.gov |
| Advanced MRI biomarkers in HD mouse models translatable to humans: nature history and response to therapeutics | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,585,010 | August 1, 2022 | July 31, 2027 | DUAN, WENZHEN | reporter.nih.gov |
| Viral Noncoding RNAs and Cell Transformation | NIH | National Cancer Institute | 2022 to 2025 | $2,579,432 | January 20, 2022 | December 31, 2026 | STEITZ, JOAN A. | reporter.nih.gov |
| Regeneration of the Immune System after Radiation Exposure | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,571,006 | August 18, 2022 | June 30, 2027 | GUHA, CHANDAN | reporter.nih.gov |
| Functional roles of lymphatics in organogenesis and tissue repair | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,543,362 | January 7, 2021 | December 31, 2025 | OLIVER, GUILLERMO C | reporter.nih.gov |
| COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children | NIH | National Cancer Institute | 2022 to 2025 | $2,523,182 | March 1, 2022 | February 28, 2026 | MESHINCHI, SOHEIL | reporter.nih.gov |
| Lymph Node Quantification System for Multisite Clinical Trials | NIH | National Cancer Institute | 2021 to 2025 | $2,503,247 | September 1, 2019 | February 28, 2030 | KIKINIS, RON | reporter.nih.gov |
| Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,499,820 | September 9, 2022 | August 31, 2028 | WANG, XIULI | reporter.nih.gov |
| Defining the role of lymphatic vessels in wound healing | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,493,383 | April 1, 2021 | March 31, 2027 | HORSLEY, VALERIE | reporter.nih.gov |
| mTORC1 and WNT in lung mesenchyme | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,493,165 | July 1, 2021 | June 30, 2025 | KRYMSKAYA, VERA P | reporter.nih.gov |
| Tailoring CAR T cell therapy for Hodgkin Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,475,444 | July 1, 2020 | June 30, 2026 | SAVOLDO, BARBARA | reporter.nih.gov |
| Diagnosis of indeterminate brain lesions using MRI-based machine learning and polygenic risk models | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,473,627 | August 15, 2020 | December 31, 2025 | ECKEL PASSOW, JEANETTE E | reporter.nih.gov |
| Genome Architecture in Human Germinal Center B Cell Development, Malignancy, and Somatic Hypermutation | NIH | National Cancer Institute | 2021 to 2024 | $2,471,907 | September 15, 2020 | August 31, 2025 | SCHATZ, DAVID G. | reporter.nih.gov |
| Targeting LIGHT for treatment of glomerulonephritis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $2,466,907 | September 1, 2025 | August 31, 2029 | KASINATH, VIVEK | reporter.nih.gov |
| New way in delivering immunomodulatory drugs in T1D | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,465,695 | February 17, 2022 | January 31, 2026 | ABDI, REZA | reporter.nih.gov |
| Brain lymphatic activation for craniosynostosis and Alzheimer’s disease | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $2,461,369 | June 1, 2024 | May 31, 2027 | CHEN, JIANFU | reporter.nih.gov |
| Pathogenesis and Treatment of Kaposiform Lymphangiomatosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,461,005 | January 1, 2022 | December 31, 2025 | LE CRAS, TIMOTHY DAVID | reporter.nih.gov |
| SYK and ZAP70 kinases in lymphocyte selection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,450,839 | February 1, 2022 | January 31, 2027 | MÜSCHEN, MARKUS | reporter.nih.gov |
| Regulation of T cell exit from non-lymphoid tissues | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,444,862 | December 1, 2010 | December 31, 2027 | SCHWAB, SUSAN RUTH | reporter.nih.gov |
| Comparative-Effectiveness of Pretreatment Lung Cancer Nodal Staging | NIH | National Cancer Institute | 2022 to 2025 | $2,437,399 | January 17, 2022 | June 30, 2026 | FARJAH, FARHOOD | reporter.nih.gov |
| The Roles of Lymphoid Tissue Microenvironments in Guiding the Immune Response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,433,851 | February 17, 2018 | January 31, 2028 | GERNER, MICHAEL | reporter.nih.gov |
| Quantitative Imaging of Brain Glymphatic Function in Humans | NIH | National Institute on Aging | 2021 to 2024 | $2,426,232 | April 15, 2020 | February 28, 2026 | DONAHUE, MANUS J | reporter.nih.gov |
| Progenitor Cells for High Endothelium in the Immune Response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,423,970 | September 25, 2017 | April 30, 2028 | BUTCHER, EUGENE C | reporter.nih.gov |
| EPHB4-RASA1 regulation of lymphatic vessel valve development and function | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,422,817 | April 1, 2015 | January 31, 2026 | KING, PHILIP D | reporter.nih.gov |
| Reciprocal VEGFC/VEGFR3-CDH5 regulation of lymphatic and sinusoidal vascular growth | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,421,054 | May 1, 2022 | April 30, 2026 | KAHN, MARK L | reporter.nih.gov |
| Defining and exploiting EBV-infected cell heterogeneity in non-Hodgkin lymphomas | NIH | National Cancer Institute | 2022 to 2025 | $2,415,701 | September 19, 2022 | August 31, 2027 | LUFTIG, MICAH ALAN | reporter.nih.gov |
| Metabolic Imaging of Targeted Therapies in Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,412,354 | January 17, 2022 | December 31, 2026 | NATH, KAVINDRA | reporter.nih.gov |
| Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,410,423 | August 1, 2021 | July 31, 2026 | IQBAL, JAVEED | reporter.nih.gov |
| DISSECTING THE ROLE OF PRDM15 IN NORMAL HEMATOPOIESIS AND B-CELL MALIGNANCIES | NIH | National Cancer Institute | 2021 to 2025 | $2,407,764 | December 9, 2020 | November 30, 2025 | GUCCIONE, ERNESTO | reporter.nih.gov |
| LTBR CARs as next-generation therapies for R/R lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $2,404,689 | April 10, 2023 | March 31, 2028 | SANJANA, NEVILLE | reporter.nih.gov |
| Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings | NIH | National Cancer Institute | 2022 to 2024 | $2,400,702 | March 1, 2022 | March 31, 2026 | GOLDBERG, MANIJEH N | reporter.nih.gov |
| Escape from CAR T surveillance through lineage plasticity | NIH | National Cancer Institute | 2022 to 2025 | $2,388,454 | April 1, 2022 | March 31, 2027 | ERNST, PATRICIA | reporter.nih.gov |
| (PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment | NIH | National Cancer Institute | 2021 to 2024 | $2,387,284 | May 15, 2020 | April 30, 2026 | CESARMAN, ETHEL | reporter.nih.gov |
| Interaction between microvascular function and CSF clearance in Lewy body dementia | NIH | National Institute on Aging | 2023 | $2,387,139 | June 1, 2023 | May 31, 2026 | HUA, JUN | reporter.nih.gov |
| Mechanistic Elucidation of Class Switch Recombination and Somatic Hypermutation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,375,342 | July 1, 2009 | January 31, 2026 | CHAUDHURI, JAYANTA | reporter.nih.gov |
| Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,374,490 | July 10, 2014 | June 30, 2025 | MOORMANN, ANN M | reporter.nih.gov |
| Lymphatics in the liver | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,371,957 | July 1, 2022 | June 30, 2027 | IWAKIRI, YASUKO | reporter.nih.gov |
| In vivo Evaluation of Lymph Nodes Using Quantitative Ultrasound | NIH | National Cancer Institute | 2023 to 2025 | $2,359,210 | August 2, 2023 | July 31, 2028 | MAMOU, JONATHAN | reporter.nih.gov |
| Development of A HTLV-1 Vaccine | NIH | National Cancer Institute | 2021 to 2024 | $2,357,214 | March 3, 2021 | February 28, 2026 | BARBER, GLEN N. | reporter.nih.gov |
| Inflammatory changes and glymphatic dysfunction in carbon monoxide neuropathology | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,357,066 | March 1, 2022 | February 28, 2027 | THOM, STEPHEN RAYMOND | reporter.nih.gov |
| Lymphatic ERG signaling in scleroderma fibrosis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,352,935 | July 7, 2022 | May 31, 2027 | TROJANOWSKA, MARIA | reporter.nih.gov |
| Mechanisms of progression of vascular malformation to lymphangiosarcoma | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,351,725 | April 8, 2003 | June 30, 2027 | GUAN, JUN-LIN | reporter.nih.gov |
| Role of the stromal microenvironment in B-cell lymphoma progression and immune escape | NIH | National Cancer Institute | 2021 to 2024 | $2,350,136 | December 1, 2019 | November 30, 2025 | CERCHIETTI, LEANDRO C | reporter.nih.gov |
| CSF Clearance in Sporadic Alzheimer's Disease | NIH | National Institute on Aging | 2021 to 2023 | $2,348,572 | August 15, 2019 | April 30, 2025 | LI, YI | reporter.nih.gov |
| Models and methods for automatically measuring disease body-wide and staging disease via FDG-PET/CT in Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,339,662 | August 12, 2021 | July 31, 2025 | UDUPA, JAYARAM K | reporter.nih.gov |
| Host pathways regulating Epstein-Barr virus-mediated B cell growth transformation | NIH | National Cancer Institute | 2021 to 2025 | $2,339,012 | September 1, 2011 | July 31, 2026 | LUFTIG, MICAH ALAN | reporter.nih.gov |
| Lymph Node Delivery in Transplantation | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,334,750 | June 18, 2022 | May 31, 2027 | ABDI, REZA | reporter.nih.gov |
| Efferocytosis-Directed Inflammation Resolution and Repair in the Hypoxic Heart | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,334,070 | April 1, 2014 | January 31, 2025 | THORP, EDWARD BENJAMIN | reporter.nih.gov |
| Dissecting immune surveillance to gammaherpesviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,328,052 | September 16, 2020 | August 31, 2025 | USHERWOOD, EDWARD J | reporter.nih.gov |
| Mechanisms regulating KSHV transcription elongation and termination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,318,808 | June 10, 2021 | May 31, 2027 | CONRAD, NICHOLAS K | reporter.nih.gov |
| Map Paravascular Fluid Dynamic Signatures of Key Aging and AD Processes Using Dynamics Diffusion-Weighted Imaging | NIH | National Institute on Aging | 2023 | $2,317,887 | September 15, 2023 | August 31, 2026 | WEN, QIUTING | reporter.nih.gov |
| Regulatory T Cells and Lymphatic Endothelial Cells: Regulatory Interactions for Migration and Suppression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,317,500 | December 1, 2004 | March 31, 2026 | BROMBERG, JONATHAN S | reporter.nih.gov |
| Aged T-cell-derived cytokines impact meningeal lymphatics and contribute to AD | NIH | National Institute on Aging | 2022 to 2025 | $2,309,676 | August 17, 2022 | April 30, 2027 | KIPNIS, JONATHAN | reporter.nih.gov |
| Development of a human intestinal microphysiological system for the study of immune responses to protozoan parasites | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,307,273 | July 5, 2023 | June 30, 2028 | KNOLL, LAURA J | reporter.nih.gov |
| The role of N6-methyladenosine RNA modification in programmed and aberrant DNA mutagenesis in B cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,301,592 | September 9, 2020 | November 30, 2029 | BASU, UTTIYA | reporter.nih.gov |
| Causal Representation Learning for the Spatial Analysis of Transcriptomic and Imaging Data in Tissue Contexts | NIH | National Center for Complementary & Integrative Health | 2022 to 2025 | $2,298,000 | September 15, 2022 | August 31, 2027 | UHLER, CAROLINE | reporter.nih.gov |
| Novel CAR T cell engineering strategies for effective eradication of solid and liquid tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,291,623 | September 20, 2019 | May 31, 2030 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| Enabling AI-based Mouse Genetic Discovery | NIH | Office of the Director, National Institutes of Health | 2023 to 2025 | $2,289,285 | August 1, 2023 | July 31, 2027 | PELTZ, GARY A | reporter.nih.gov |
| Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $2,289,208 | May 1, 2021 | April 30, 2027 | NIXON, DOUGLAS F | reporter.nih.gov |
| Regulation of EBV Latency by Purine Metabolism and Signaling | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,287,875 | May 19, 2021 | April 30, 2027 | TEMPERA, ITALO | reporter.nih.gov |
| A Critical Role for Hypoxia-Inducible Factors in Lymphedema | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,285,302 | August 1, 2021 | July 31, 2025 | JIANG, XINGUO | reporter.nih.gov |
| Uterine signaling networks in the pathogenesis of pulmonary lymphangioleiomyomatosis (LAM) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,284,413 | July 21, 2020 | June 30, 2025 | XU, YAN | reporter.nih.gov |
| Biology of Lymphangiogenesis in the Adult Lung | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,281,864 | July 1, 2022 | June 30, 2027 | JONES, MATTHEW ROBERT | reporter.nih.gov |
| Targeting c-Myc stability in c-Myc overexpressing large B-cell lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,273,181 | April 1, 2022 | March 31, 2027 | ALINARI, LAPO | reporter.nih.gov |
| XBP1 Inhibition and STING activation for the treatment of cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,273,099 | April 8, 2022 | March 31, 2027 | HU, CHIH-CHI ANDREW | reporter.nih.gov |
| Assessing CSF flow dynamics in pediatric hemorrhagic hydrocephalus | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,268,152 | April 1, 2022 | March 31, 2027 | SEVICK, EVA M. | reporter.nih.gov |
| IRI, innate immunity and transplant rejection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,266,791 | March 15, 2021 | February 28, 2026 | ABDI, REZA | reporter.nih.gov |
| Mechanisms of cell fate specification by glycosylation | NIH | National Institute of General Medical Sciences | 2025 | $2,252,479 | September 1, 2025 | July 31, 2029 | KASPER, DIONNA | reporter.nih.gov |
| Role of apoE-mediated meningeal lymphatic remodeling in the pathophysiology of Alzheimer’s disease | NIH | National Institute on Aging | 2023 | $2,250,745 | September 1, 2023 | August 31, 2026 | DA MESQUITA, SANDRO | reporter.nih.gov |
| Aging and Exercise Effects of Dural Lymphatic Clearance in Healthy Human and Diabetic Brains | NIH | National Institute on Aging | 2022 | $2,247,456 | May 1, 2022 | April 30, 2025 | MIYAZAKI, MITSUE | reporter.nih.gov |
| Overcoming ibrutinib resistance in mantle cell lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $2,239,026 | February 1, 2021 | January 31, 2026 | DANILOV, ALEXEY V. | reporter.nih.gov |
| Mechanisms that alter lymphatic transport in inflammatory bowel disease | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,237,567 | February 7, 2022 | January 31, 2027 | RANDOLPH, GWENDALYN J | reporter.nih.gov |
| Targeting Epstein-Barr Virus Super-Enhancer | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,237,500 | March 1, 2016 | March 31, 2026 | ZHAO, BO | reporter.nih.gov |
| Roles of Coactivator-Associated Arginine Methyltransferase 1 in B cell activation and lymphomagenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,226,458 | April 1, 2021 | March 31, 2027 | GREEN, MICHAEL RICHARD | reporter.nih.gov |
| Defining the induction and maintenance of myelin-specific tolerance in T cells and B cells using local lymph node depots | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,215,775 | February 1, 2022 | January 31, 2027 | JEWELL, CHRISTOPHER M | reporter.nih.gov |
| Salt Mediated Cross Talk Between Lymphatic Vessels and Immune Cells in Kidney Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,215,581 | June 2, 2023 | April 30, 2028 | KON, VALENTINA | reporter.nih.gov |
| Gammaherpesvirus miRNA suppression of EWSR1 in GC B cell infection and lymphomagenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,206,513 | August 1, 2021 | July 31, 2026 | TIBBETTS, SCOTT A. | reporter.nih.gov |
| Engineering the Stem Cell Microenvironment for Lymphatic Regeneration | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,205,356 | July 1, 2021 | May 31, 2027 | HANJAYA-PUTRA, DONNY | reporter.nih.gov |
| Gut region-specific mechanisms that limit dissemination of microbial signals from the intestine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,205,002 | September 8, 2021 | June 30, 2026 | RANDOLPH, GWENDALYN J | reporter.nih.gov |
| A high-throughput platform to identify selective allosteric inhibitors of the PLC-y isozymes | NIH | National Cancer Institute | 2021 to 2024 | $2,198,247 | May 1, 2021 | April 30, 2026 | ZHANG, QISHENG | reporter.nih.gov |
| Targeting SOX11 in Mantle Cell Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,197,928 | September 1, 2020 | November 30, 2025 | PAREKH, SAMIR | reporter.nih.gov |
| The role of DNA-PKcs in DNA repair, lymphocyte development, RNA metabolism and tumor suppression | NIH | National Cancer Institute | 2022 to 2025 | $2,194,376 | July 1, 2022 | June 30, 2027 | ZHA, SHAN | reporter.nih.gov |
| Acute Imposition of Fontan Physiology in The Single Ventricle Patient: Effects on Fibrosis, Function and Drug Intervention | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,190,858 | July 1, 2020 | June 30, 2026 | FOGEL, MARK A | reporter.nih.gov |
| Mapping & quantifying lymphatic drainage of the arm's alternate pathway | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,188,750 | January 26, 2021 | December 31, 2026 | SINGHAL, DHRUV | reporter.nih.gov |
| Mechanisms controlling stochastic gene expression during eye development | NIH | National Eye Institute | 2021 to 2025 | $2,184,314 | August 1, 2015 | June 30, 2029 | JOHNSTON, ROBERT JOHN | reporter.nih.gov |
| Role of BCL10 somatic mutations in lymphomagenesis and response to BCR-targeted therapies | NIH | National Cancer Institute | 2021 to 2024 | $2,183,689 | July 1, 2020 | June 30, 2026 | CERCHIETTI, LEANDRO C | reporter.nih.gov |
| Glymphatic impairment as a crucial factor in particulate matter exposure related development of Alzheimer's disease pathology | NIH | National Institute on Aging | 2023 to 2025 | $2,180,411 | September 1, 2023 | May 31, 2028 | HUSSAIN, RASHAD | reporter.nih.gov |
| Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study | NIH | National Cancer Institute | 2022 to 2024 | $2,178,209 | January 1, 2020 | December 31, 2025 | HILL, JOSHUA AIDEN | reporter.nih.gov |
| Biochemical and functional characterization of a novel anti-inflammatory biogenic amine | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,177,069 | July 6, 2023 | June 30, 2028 | SANTAMBROGIO, LAURA | reporter.nih.gov |
| Hydrogel-based Organoids of African-American Lymphomas to Study B Cell Receptor Pathway Inhibitors | NIH | National Cancer Institute | 2022 to 2025 | $2,169,356 | August 1, 2022 | July 31, 2027 | SINGH, ANKUR | reporter.nih.gov |
| Defining the Mechanisms of Lymphatic Vascular Growth and Function | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,169,318 | June 1, 2016 | November 30, 2026 | SRINIVASAN, RAJANARAYANAN S | reporter.nih.gov |
| Exploring the potential of TET inhibition in cancer immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $2,169,214 | July 1, 2020 | June 30, 2025 | RAO, ANJANA | reporter.nih.gov |
| New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,168,990 | June 1, 2020 | May 31, 2025 | CLEVELAND, JOHN L. | reporter.nih.gov |
| Mechanisms of racial disparity in breast cancer-related lymphedema | NIH | National Cancer Institute | 2023 to 2025 | $2,166,923 | January 1, 2023 | December 31, 2027 | MEHRARA, BABAK J | reporter.nih.gov |
| Functional characterization and rational therapeutic targeting of 18q DNA copy number gains in diffuse large B-cell lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $2,164,975 | December 1, 2020 | November 30, 2025 | GREEN, MICHAEL RICHARD | reporter.nih.gov |
| Cardiovascular potassium channels: From molecular basis to disease therapeutics | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,160,901 | January 1, 2024 | December 31, 2030 | NICHOLS, COLIN G | reporter.nih.gov |
| The transcription factor c-MYC in lymphocyte expansion and restriction of stemness | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,159,884 | September 25, 2017 | July 31, 2028 | EGAWA, TAKESHI | reporter.nih.gov |
| Role of S.aureus in Cutaneous T Cell Lymphoma Pathogenesis | NIH | National Cancer Institute | 2022 to 2025 | $2,150,022 | May 10, 2022 | April 30, 2027 | KORALOV, SERGEI BORISOVICH | reporter.nih.gov |
| Interrogating the in vivo pharmacokinetics of armored CARs with radiohapten capture | NIH | National Cancer Institute | 2021 to 2024 | $2,149,252 | July 7, 2021 | January 1, 2025 | KREBS, SIMONE | reporter.nih.gov |
| Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers | NIH | National Cancer Institute | 2022 to 2025 | $2,147,095 | September 7, 2022 | July 31, 2027 | SALVINO, JOSEPH M | reporter.nih.gov |
| Site-Specific Recombination in Human Health & Disease | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,145,000 | June 1, 2016 | May 31, 2027 | LIEBER, MICHAEL R | reporter.nih.gov |
| Protein tyrosine phosphatase non-receptor 14 in vascular stability and remodeling | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,141,603 | March 15, 2023 | February 28, 2027 | AKHURST, ROSEMARY J | reporter.nih.gov |
| Role of PXR in drug-elicited cardiovascular disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,135,638 | December 15, 2022 | November 30, 2026 | ZHOU, CHANGCHENG | reporter.nih.gov |
| Unraveling the Pathophysiology of Neurotoxicity Induced by CAR T-cells | NIH | National Cancer Institute | 2022 to 2025 | $2,131,216 | August 8, 2022 | July 31, 2027 | PENNELL, CHRISTOPHER A | reporter.nih.gov |
| Th17 generation, action and therapeutic relevance in chronic lymphocytic leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,127,395 | December 1, 2019 | November 30, 2025 | CHIORAZZI, NICHOLAS | reporter.nih.gov |
| RNA-directed targeting of AID in immunity and cancer | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,124,000 | February 1, 2016 | June 30, 2027 | CHAUDHURI, JAYANTA | reporter.nih.gov |
| A novel strategy for transcriptional reprogramming of lymphoid leukemia cells | NIH | National Cancer Institute | 2022 to 2025 | $2,123,519 | January 1, 2022 | December 31, 2026 | CALABRETTA, BRUNO | reporter.nih.gov |
| Cerebrospinal fluid exchange in Alzheimer's disease characterized by advanced MRI techniques | NIH | National Institute on Aging | 2023 to 2025 | $2,119,671 | December 15, 2022 | November 30, 2027 | XU, JIADI | reporter.nih.gov |
| Lymphatic Dysfunction in the Pathogenesis of COPD | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,118,673 | April 1, 2023 | January 31, 2028 | REED, HASINA OUTTZ | reporter.nih.gov |
| Slow wave sleep as a biomarker of rehabilitation-induced cognitive improvement in Parkinson's disease | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,113,374 | April 1, 2021 | March 31, 2027 | AMARA, AMY WILLIS | reporter.nih.gov |
| Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $2,108,871 | June 1, 2021 | May 31, 2027 | YANG, YIBIN | reporter.nih.gov |
| AQP4 and glymphatic function in post-stroke recovery | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $2,108,706 | July 1, 2022 | June 30, 2027 | YU, XIN | reporter.nih.gov |
| The 10,000 Families Cohort: a new study to understand the environmental causes of cancer | NIH | National Cancer Institute | 2021 to 2022 | $2,106,878 | September 24, 2021 | August 31, 2023 | POYNTER, JENNY N. | reporter.nih.gov |
| Lymph node-targeted multistage chemoimmunotherapy for lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,094,096 | April 1, 2020 | March 31, 2026 | THOMAS, SUSAN NAPIER | reporter.nih.gov |
| New Materials to Deliver mRNA: Applications in Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $2,075,015 | August 13, 2020 | April 30, 2025 | WAYMOUTH, ROBERT M. | reporter.nih.gov |
| Sleep-dependent mechanisms of improving cerebral blood flow and reducing Alzheimer's disease progression by photobiomodulation with near-infrared light | NIH | National Institute on Aging | 2023 to 2025 | $2,074,140 | May 15, 2023 | January 31, 2028 | GERASHCHENKO, DMITRY | reporter.nih.gov |
| MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER | NIH | National Cancer Institute | 2022 to 2025 | $2,073,174 | April 12, 2022 | March 31, 2027 | RUELLA, MARCO | reporter.nih.gov |
| TSC Proteins in the Lymphatic Vasculature | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,069,522 | July 1, 2023 | June 30, 2028 | YANG, YING | reporter.nih.gov |
| Understanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in Lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $2,068,451 | March 13, 2023 | February 29, 2028 | KHARAS, MICHAEL | reporter.nih.gov |
| Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $2,064,042 | July 16, 2015 | November 30, 2026 | CHIARLE, ROBERTO | reporter.nih.gov |
| Investigating the EBV methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva | NIH | National Cancer Institute | 2023 to 2025 | $2,053,910 | September 8, 2023 | August 31, 2028 | AMBINDER, RICHARD FREDERICK | reporter.nih.gov |
| Targeting p38 gamma signaling to advance Cutaneous T Cell Lymphoma Therapy | NIH | National Cancer Institute | 2021 to 2023 | $2,047,877 | December 1, 2018 | November 30, 2024 | ROSEN, STEVEN TERRY | reporter.nih.gov |
| Regulation of Lymphatic Endothelial Cell Junction and Drainage | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,042,340 | July 1, 2022 | June 30, 2027 | LEE, ESAK | reporter.nih.gov |
| Mechanism of Eukaryotic Environmental Mutagenesis | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $2,037,163 | September 15, 2017 | May 31, 2026 | WALKER, GRAHAM C | reporter.nih.gov |
| GDANII_DLBCL cohort analysis and cloud costs | NIH | National Cancer Institute | 2021 to 2025 | $2,032,755 | December 1, 2024 | August 31, 2025 | GETZ, GAD A | reporter.nih.gov |
| Regulation and modeling of transport across tissue barriers | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,031,571 | July 1, 2021 | May 31, 2026 | MAISEL, KATHARINA | reporter.nih.gov |
| Investigating the role of CSF production and circulation in aging and Alzheimer's disease | NIH | National Institute on Aging | 2023 to 2025 | $2,025,110 | August 1, 2023 | April 30, 2028 | LUO, YU | reporter.nih.gov |
| A spatially organized microphysiological model of a human lymph node | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $2,024,625 | September 17, 2019 | June 30, 2025 | POMPANO, REBECCA R | reporter.nih.gov |
| Visualizing vascular mechanisms of lipedema | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,023,233 | April 20, 2021 | October 21, 2024 | CRESCENZI, RACHELLE L | reporter.nih.gov |
| Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,022,453 | April 6, 2021 | March 31, 2027 | YANG, YIBIN | reporter.nih.gov |
| Molecular Biomarkers in pathogenesis of Lymphangioleiomyomatosis (LAM) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,022,093 | September 10, 2023 | June 30, 2027 | D'ARMIENTO, JEANINE M | reporter.nih.gov |
| Interstitial fluid flow in Alzheimer's Disease Progression | NIH | National Institute on Aging | 2021 | $2,021,966 | May 1, 2021 | April 30, 2024 | MUNSON, JENNIFER M | reporter.nih.gov |
| Therapeutic targeting of SIRT3 for aggressive and refractory lymphomas | NIH | National Cancer Institute | 2023 to 2025 | $2,005,584 | March 2, 2023 | February 29, 2028 | LI, MENG | reporter.nih.gov |
| Central tolerance mechanisms in B-cell malignancies | NIH | National Cancer Institute | 2021 to 2025 | $2,003,674 | June 1, 2011 | June 30, 2027 | MÜSCHEN, MARKUS | reporter.nih.gov |
| Novel ocular imaging and molecular analysis of anterior eye segment for glaucoma | NIH | National Eye Institute | 2023 to 2025 | $2,003,442 | March 1, 2023 | February 29, 2028 | KUME, TSUTOMU | reporter.nih.gov |
| Cardiac Lymphatics in Development and Repair | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,001,701 | April 1, 2016 | June 30, 2025 | CARON, KATHLEEN M | reporter.nih.gov |
| Targeting the vasculature to enhance anti-tumor immunity | NIH | National Cancer Institute | 2021 to 2025 | $2,001,230 | September 1, 2014 | June 30, 2030 | DUDLEY, ANDREW CARL | reporter.nih.gov |
| Treg-depleting immunotherapy | NIH | National Cancer Institute | 2021 to 2022 | $2,000,000 | September 7, 2020 | September 30, 2024 | SUZDAK, PETER DAVID | reporter.nih.gov |
| Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients | NIH | National Cancer Institute | 2022 to 2023 | $1,999,998 | June 10, 2022 | April 30, 2024 | DEISHER, THERESA | reporter.nih.gov |
| CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients | NIH | National Cancer Institute | 2024 to 2025 | $1,999,990 | September 20, 2024 | August 31, 2026 | BERTOLINO, ARTHUR P | reporter.nih.gov |
| Dual-targeting allogeneic CAR T-cells for universal therapy of T-cell malignancies | NIH | National Cancer Institute | 2024 to 2025 | $1,999,703 | September 1, 2024 | August 31, 2027 | HEIN, SARAH MARIE | reporter.nih.gov |
| A Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NHL or CLL | NIH | National Cancer Institute | 2021 to 2022 | $1,998,672 | September 16, 2021 | August 31, 2023 | LITCHMAN, MANUEL | reporter.nih.gov |
| An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms Macroglobulinemia | NIH | National Cancer Institute | 2021 to 2023 | $1,994,489 | September 1, 2021 | August 31, 2024 | LONGCOR, JARROD | reporter.nih.gov |
| Molecular control of germinal center selection and affinity maturation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,993,832 | August 15, 2018 | May 31, 2029 | VICTORA, GABRIEL D | reporter.nih.gov |
| Molecular mechanisms governing the ubiquitination signaling during KSHV cell entry and tumorigenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,992,560 | July 1, 2021 | June 30, 2027 | SHEMBADE, NOULA DATTU | reporter.nih.gov |
| The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $1,989,049 | July 1, 2021 | June 30, 2026 | NGO, VU NGUYEN | reporter.nih.gov |
| Optimizing immunoradiotherapy for HNSCC | NIH | National Cancer Institute | 2023 to 2025 | $1,988,993 | September 25, 2023 | August 31, 2028 | CALIFANO, JOSEPH A | reporter.nih.gov |
| Cooperation between lymphatic stroma and hematopoietic cells shapes protective immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,983,598 | February 16, 2016 | March 31, 2027 | TAMBURINI, BETH ANN | reporter.nih.gov |
| Role of novel onco-histone mutations in B-cell malignancies | NIH | National Cancer Institute | 2021 to 2023 | $1,967,972 | August 1, 2019 | July 31, 2025 | CESARMAN, ETHEL | reporter.nih.gov |
| Exosomes in HNSCC Progression | NIH | National Cancer Institute | 2021 to 2025 | $1,966,471 | May 1, 2021 | April 30, 2027 | WEAVER, ALISSA M | reporter.nih.gov |
| Regulation of B cell signaling in autoimmunity by TRAF3 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,964,463 | August 1, 2021 | July 31, 2026 | BISHOP, GAIL A. | reporter.nih.gov |
| Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase Inhibition | NIH | National Cancer Institute | 2021 to 2024 | $1,963,552 | March 9, 2020 | February 28, 2026 | NATH, KAVINDRA | reporter.nih.gov |
| Role of Skeletal Muscle Lymphatics in Duchenne Muscular Dystrophy Regulation | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,963,162 | May 24, 2022 | April 30, 2027 | MUTHUCHAMY, MARIAPPAN | reporter.nih.gov |
| Retinoic Acid Induced Lymphangiogenesis for Post-surgical Lymphedema | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,961,343 | September 1, 2021 | November 30, 2023 | WONG, ALEX K. | reporter.nih.gov |
| Identifying Therapeutic Targets for Stage III Melanoma | NIH | National Cancer Institute | 2021 to 2024 | $1,959,905 | December 4, 2019 | November 30, 2025 | GANESAN, ANAND K | reporter.nih.gov |
| Neuroimaging the impact of respiration and respiratory-gated neuromodulation on human glymphatic physiology | NIH | National Center for Complementary & Integrative Health | 2022 to 2025 | $1,959,742 | April 1, 2021 | December 31, 2026 | LEWIS, LAURA DIANE | reporter.nih.gov |
| Chronic Alcohol, Dementia, and CNS Fluid Homeostasis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $1,959,740 | September 20, 2022 | August 31, 2027 | MASON, GRAEME F | reporter.nih.gov |
| Ultrasensitive, High-Specificity Rapid Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,954,629 | May 1, 2022 | June 30, 2027 | BIAMONTE, MARCO ANTONIO | reporter.nih.gov |
| Imaging sodium and lymphatics in lymphedema | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,947,844 | January 25, 2021 | October 31, 2024 | CRESCENZI, RACHELLE L | reporter.nih.gov |
| Epigenomic Control of KSHV Latency | NIH | National Cancer Institute | 2021 to 2025 | $1,945,305 | April 1, 2006 | June 30, 2028 | LIEBERMAN, PAUL M. | reporter.nih.gov |
| Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $1,944,040 | March 1, 2020 | February 28, 2025 | DUCKETT, DEREK RONALD | reporter.nih.gov |
| Complement and Circadian Interactions in Inflammation and Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,941,040 | April 15, 2021 | March 31, 2026 | MAHAN, KRISTIN ECKEL | reporter.nih.gov |
| Regulation of Neuroinflammation by Meningeal Lymphatics | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,940,296 | August 15, 2022 | July 31, 2027 | FABRY, ZSUZSANNA | reporter.nih.gov |
| (PQ4) Role of HIV-induced PLK1 Activation in Regulation of gamma-Herpesvirus Reservoirs in Lymphocytes | NIH | National Cancer Institute | 2021 to 2025 | $1,939,971 | May 11, 2021 | April 30, 2027 | SANTOSO, NETTY G | reporter.nih.gov |
| Therapeutic Targeting a Non-Hodgkin Lymphoma Driver Using AI | NIH | National Cancer Institute | 2023 to 2025 | $1,935,453 | December 16, 2022 | November 30, 2027 | LI, YONG | reporter.nih.gov |
| Multi-scale modeling of lymphatic vasculature growth and adaptation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,925,326 | May 12, 2020 | April 30, 2025 | DIXON, JAMES BRANDON | reporter.nih.gov |
| Dissecting the role of EBV and P. falciparum in endemic Burkitt lymphoma pathogenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,923,862 | August 14, 2019 | January 31, 2025 | LUFTIG, MICAH A. | reporter.nih.gov |
| Defining the protective efficacy of antibodies against the EBV gH/gL glycoprotein complex | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,920,168 | August 9, 2019 | July 31, 2025 | MCGUIRE, ANDREW | reporter.nih.gov |
| Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas | NIH | National Cancer Institute | 2022 to 2025 | $1,917,273 | July 20, 2022 | June 30, 2027 | ORLOWSKI, ROBERT ZYGMUNT | reporter.nih.gov |
| A Multifaceted Radiomics Model to Predict Cervical Lymph Node Metastasis for Involved Nodal Radiation Therapy | NIH | National Cancer Institute | 2022 to 2025 | $1,909,407 | July 1, 2022 | June 30, 2027 | WANG, JING | reporter.nih.gov |
| Regulation of Adipose-Lymphatic Cross-talk | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,905,751 | July 15, 2021 | April 30, 2026 | ROSEN, EVAN D | reporter.nih.gov |
| The effect of inflammation and damage to lymph node structures on durable protective immunity following vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,904,986 | February 25, 2019 | January 31, 2024 | SCHACKER, TIMOTHY W | reporter.nih.gov |
| A Nanocarrier Platform for Targeting Schlemm's Canal Cells | NIH | National Eye Institute | 2022 to 2025 | $1,902,955 | September 30, 2022 | July 31, 2026 | JOHNSON, MARK | reporter.nih.gov |
| The role of NUDT16 in DNA damage response and tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $1,900,364 | December 1, 2018 | July 31, 2029 | GONG, ZIHUA | reporter.nih.gov |
| Mechanisms of Lymphomagenesis of Skin Resident Gamma Delta T cells | NIH | National Cancer Institute | 2022 to 2025 | $1,898,706 | December 13, 2021 | November 30, 2026 | LE POOLE, I. CAROLINE | reporter.nih.gov |
| Lymphatic pacemaking and pumping in lymphedema: function, dysfunction, and rescue | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,896,927 | April 1, 2015 | December 31, 2024 | DAVIS, MICHAEL JOHN | reporter.nih.gov |
| Integration of germline and tumor genomes in CLL | NIH | National Cancer Institute | 2021 to 2023 | $1,895,188 | December 6, 2018 | May 31, 2024 | SLAGER, SUSAN L | reporter.nih.gov |
| Non-canonical Wnt-Receptor Signaling and Targeted Therapies | NIH | National Cancer Institute | 2021 to 2023 | $1,888,486 | April 15, 2019 | March 31, 2025 | KIPPS, THOMAS J | reporter.nih.gov |
| Development of an ultrasound detectable, migration-resistant biopsy marker for improving care in patients with breast cancer | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $1,884,589 | December 15, 2022 | November 30, 2026 | URBAN, MATTHEW WILLIAM | reporter.nih.gov |
| Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination | NIH | National Cancer Institute | 2021 to 2025 | $1,875,709 | December 1, 2024 | November 30, 2026 | BRODY, JOSHUA D | reporter.nih.gov |
| The Role of lymphatic endothelium in the developing thymus | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,874,629 | June 16, 2023 | May 31, 2028 | CROOKS, GAY M | reporter.nih.gov |
| Role of CREBBP missense mutations in lymphomagenesis | NIH | National Cancer Institute | 2022 to 2025 | $1,867,100 | January 1, 2022 | December 31, 2026 | PASQUALUCCI, LAURA | reporter.nih.gov |
| Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,861,249 | July 1, 2023 | August 31, 2027 | GIBBONS, HUNTER RAMSDELL | reporter.nih.gov |
| Exercise as an Immune Adjuvant for Gamma Delta T-cell Therapies in Hematologic Malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,860,326 | April 1, 2023 | March 31, 2028 | SIMPSON, RICHARD J | reporter.nih.gov |
| Understanding Richter's Transformation in the targeted therapies era | NIH | National Cancer Institute | 2021 to 2024 | $1,854,920 | September 11, 2020 | May 31, 2025 | LAPALOMBELLA, ROSA | reporter.nih.gov |
| Neoadjuvant immunoradiotherapy for HPV mediated oropharynx cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,854,023 | September 18, 2023 | July 31, 2028 | CALIFANO, JOSEPH A | reporter.nih.gov |
| Lymph Node Structure and Function in Tolerance: Role of Laminins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,854,000 | April 20, 2015 | May 31, 2025 | BROMBERG, JONATHAN S | reporter.nih.gov |
| Mechanisms of Control of Lymphocyte Activation and Proliferation by a Critical Signaling Integrator | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,852,168 | December 1, 2019 | November 30, 2025 | POMERANTZ, JOEL L | reporter.nih.gov |
| Advancing next-generation CAR-NK therapies targeting CD5 positive T cell malignancies to the clinic | NIH | National Cancer Institute | 2025 | $1,847,485 | September 19, 2025 | August 31, 2029 | REZVANI, KATY | reporter.nih.gov |
| Enlarged Perivascular Spaces as Markers of Vascular and Alzheimer pathology: predictors, pathophysiology and clinical consequences | NIH | National Institute on Aging | 2021 to 2023 | $1,846,394 | August 1, 2019 | April 30, 2026 | ROMERO, JOSE RAFAEL | reporter.nih.gov |
| Biocompatible fluorophores for shortwave infrared imaging | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $1,841,271 | September 13, 2023 | August 31, 2027 | SLETTEN, ELLEN MAY | reporter.nih.gov |
| Protein homeostasis dysfunction in LM and VM pathobiology and therapeutic responses | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,840,645 | December 15, 2022 | November 30, 2026 | SHAWBER, CARRIE J | reporter.nih.gov |
| Epstein-Barr virus LMP1 mediated oncogenicity | NIH | National Cancer Institute | 2021 to 2025 | $1,836,181 | September 19, 2019 | March 31, 2030 | GEWURZ, BENJAMIN ELISON | reporter.nih.gov |
| Subingual-parenteral Vaccination to Prevent Oral HIV Transmission in Infants | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $1,832,540 | September 6, 2018 | June 30, 2024 | DE PARIS, KRISTINA | reporter.nih.gov |
| The role of lymph node structural organization in naïve T cell decline with age | NIH | National Institute on Aging | 2023 to 2025 | $1,828,813 | August 1, 2023 | April 30, 2028 | LANCASTER, JESSICA N | reporter.nih.gov |
| Intravenous VSV virotherapy in lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $1,828,271 | May 11, 2023 | April 30, 2028 | PENG, KAH-WHYE | reporter.nih.gov |
| Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures | NIH | National Cancer Institute | 2021 to 2025 | $1,827,310 | September 20, 2021 | August 31, 2027 | IQBAL, JAVEED | reporter.nih.gov |
| The Tumor Microenvironment and Lymphatic Remodeling in Postpartum Breast Cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,823,442 | July 1, 2022 | December 31, 2027 | MCDONALD, JASMINE ALISE | reporter.nih.gov |
| Role and Mechanisms of VAV1 alterations in Peripheral T-cell Lymphomas | NIH | National Cancer Institute | 2021 to 2025 | $1,819,525 | July 1, 2021 | May 31, 2027 | PALOMERO, TERESA | reporter.nih.gov |
| Phase one clinical trial of a novel small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein- Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic correlative studies | NIH | National Cancer Institute | 2021 to 2023 | $1,817,793 | February 1, 2019 | January 31, 2025 | COLEVAS, A. DIMITRIOS | reporter.nih.gov |
| Linking insertional mutagenesis and cell function to improve CAR T cell therapy | NIH | National Cancer Institute | 2021 to 2023 | $1,813,460 | June 1, 2019 | April 30, 2024 | BUSHMAN, FREDERIC D | reporter.nih.gov |
| Engineering the next generation nanoparticle-cyclosporine A therapy in lupus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,811,188 | September 21, 2020 | August 31, 2027 | MAJETI, RAVIKUMAR N | reporter.nih.gov |
| Genetics of LAM | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,809,373 | December 15, 2020 | November 30, 2025 | KWIATKOWSKI, DAVID J. | reporter.nih.gov |
| Background-free molecular imaging using modulated photoacoustics and targeted contrast agent | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $1,805,980 | July 1, 2020 | March 31, 2025 | DICKSON, ROBERT M | reporter.nih.gov |
| Exposing synthetic lethal vulnerabilities in EBV-positive AIDS-NHL through novel replication dependency factors | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $1,804,864 | September 4, 2023 | August 31, 2028 | BHADURI-MCINTOSH, SUMITA | reporter.nih.gov |
| Role of Sleep Disruption after mTBI as a Driver of Chronic Post-traumatic Headache | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,798,407 | July 1, 2023 | June 30, 2028 | ILIFF, JEFFREY J | reporter.nih.gov |
| Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,797,355 | July 21, 2023 | June 30, 2028 | VASU, SUMITHIRA | reporter.nih.gov |
| Targeting GSK3B in refractory B-cell malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,794,818 | July 19, 2023 | June 30, 2028 | MÜSCHEN, MARKUS | reporter.nih.gov |
| EBNA1 Inhibitor for Treatment of EBV-positive DLBCL | NIH | National Cancer Institute | 2023 to 2025 | $1,785,789 | July 7, 2023 | June 30, 2028 | LIEBERMAN, PAUL M. | reporter.nih.gov |
| Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,782,554 | June 15, 2023 | May 31, 2027 | LE POOLE, I. CAROLINE | reporter.nih.gov |
| Multi-organ culture and pumping systems for ex vivo models of immunity in hybrid tissue-chips | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,780,063 | July 19, 2023 | June 30, 2028 | POMPANO, REBECCA R | reporter.nih.gov |
| Single-cell characterization of tumor and microenvironment co-evolution in Peripheral T-cell Lymphomas | NIH | National Cancer Institute | 2021 to 2023 | $1,779,750 | August 21, 2019 | July 31, 2024 | RABADAN, RAUL | reporter.nih.gov |
| Targeted Dual Modality Imaging for Detection and Removal of Head and Neck Cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,775,469 | August 1, 2022 | July 31, 2027 | ROSENTHAL, EBEN L. | reporter.nih.gov |
| Therapeutic implication of CD38 in CLL | NIH | National Cancer Institute | 2021 to 2023 | $1,773,312 | September 4, 2019 | August 31, 2025 | CHINI, EDUARDO N | reporter.nih.gov |
| Scaling Lymphoma Diagnosis: A Cost-Effective Gene Expression Assay for Broad Implementation | NIH | National Cancer Institute | 2025 | $1,770,000 | September 17, 2025 | August 31, 2027 | BRIERCHECK, EDWARD | reporter.nih.gov |
| Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma | NIH | National Cancer Institute | 2021 to 2023 | $1,768,990 | July 4, 2019 | June 30, 2025 | RUBENSTEIN, JAMES LOUIS | reporter.nih.gov |
| Metagenomic shotgun microbial sequencing in post-transplant lymphoproliferative disorders (PTLD-MSMS) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,764,549 | June 10, 2019 | May 31, 2025 | WYLIE, KRISTINE M. | reporter.nih.gov |
| The Biology of Mutant STAT6 in Follicular Lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $1,759,271 | September 1, 2022 | August 31, 2027 | MALEK, SAMI NIMER | reporter.nih.gov |
| Lymphoid Experimental Therapeutics Platform to Study Cooperative Signaling inHuman Lymphomas | NIH | National Cancer Institute | 2021 to 2024 | $1,752,723 | July 1, 2020 | June 30, 2026 | SINGH, ANKUR | reporter.nih.gov |
| Metabolic mechanisms controlling lymphatic vessel formation | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,748,000 | September 1, 2022 | June 30, 2027 | YU, PENGCHUN | reporter.nih.gov |
| Anti-tumor potential of temperature-sensitive p53 mutants | NIH | National Cancer Institute | 2021 to 2025 | $1,747,237 | March 1, 2021 | February 28, 2027 | CHEN, JIANDONG | reporter.nih.gov |
| Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas | NIH | National Cancer Institute | 2022 to 2025 | $1,746,152 | September 20, 2022 | July 31, 2027 | JOHANNSEN, ERIC C. | reporter.nih.gov |
| Genomic biomarkers of splenic lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $1,743,045 | October 1, 2022 | November 30, 2026 | ELENITOBA-JOHNSON, KOJO S. J. | reporter.nih.gov |
| Improving CAR-T efficacy against solid tumors by expanding lymph node reservoirs of “stem-like” CAR-T cells | NIH | National Cancer Institute | 2023 to 2025 | $1,734,139 | July 1, 2023 | June 30, 2028 | SRIVASTAVA, SHIVANI | reporter.nih.gov |
| Gammaherpesvirus protein kinase: a master manipulator of the host during chronic infection. | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,730,785 | June 22, 2022 | May 31, 2028 | TARAKANOVA, VERA L. | reporter.nih.gov |
| Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL | NIH | National Cancer Institute | 2023 to 2024 | $1,730,616 | September 9, 2020 | July 31, 2025 | DESAI, AVINASH | reporter.nih.gov |
| Personalized, antigen-directed immunotherapy delivered to lymph nodes | NIH | National Cancer Institute | 2023 to 2025 | $1,728,854 | July 1, 2023 | June 30, 2027 | SEVICK, EVA M. | reporter.nih.gov |
| Molecular Basis of KSHV oncogenesis | NIH | National Cancer Institute | 2021 to 2022 | $1,726,428 | March 1, 2016 | February 28, 2023 | JUNG, JAE U | reporter.nih.gov |
| Investigating and modeling MYD88L265P and co-occurring mutations in mature B-cell malignancies | NIH | National Cancer Institute | 2022 to 2025 | $1,713,034 | August 1, 2022 | July 31, 2027 | CARRASCO, RUBEN D | reporter.nih.gov |
| Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH) | NIH | National Cancer Institute | 2024 to 2025 | $1,709,513 | September 1, 2023 | August 31, 2028 | DHARNIDHARKA, VIKAS R. | reporter.nih.gov |
| Metabolic adaptation in lymphoid malignancies | NIH | National Cancer Institute | 2021 to 2024 | $1,709,232 | December 1, 2019 | November 30, 2025 | ZHANG, JI | reporter.nih.gov |
| Dermal Lymphatic Transport and Cutaneous Immune Balance | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,703,612 | February 15, 2022 | December 31, 2026 | LUND, AMANDA W. | reporter.nih.gov |
| Preventing follicular lymphoma progression and transformation through precision therapy | NIH | National Cancer Institute | 2022 to 2025 | $1,702,539 | June 1, 2022 | December 31, 2025 | BEGUELIN, WENDY | reporter.nih.gov |
| Novel functions of CDK6 in T-cell leukemia progression | NIH | National Cancer Institute | 2021 to 2025 | $1,701,837 | August 1, 2021 | July 31, 2026 | WANG, HAIZHEN | reporter.nih.gov |
| Lymphatics and lymphangiogenesis in kidney function and inflammation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,701,639 | January 23, 2020 | November 30, 2025 | RUTKOWSKI, JOSEPH MICHAEL | reporter.nih.gov |
| Cell Intrinsic Immune Control of KSHV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,698,320 | December 1, 2019 | November 30, 2025 | KARIJOLICH, JOHN | reporter.nih.gov |
| (PQ#2) Transposable element-mediated gene regulation in KSHV-associated cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,698,320 | April 1, 2020 | March 31, 2026 | KARIJOLICH, JOHN | reporter.nih.gov |
| Mcl-1/Bfl-1 in apoptosis and signal transduction: a structure/function approach | NIH | National Cancer Institute | 2021 to 2024 | $1,694,221 | July 9, 2012 | November 30, 2025 | PELLECCHIA, MAURIZIO | reporter.nih.gov |
| BCLW in lymphoma survival and resistance to targeted BCL2 family therapies | NIH | National Cancer Institute | 2021 to 2025 | $1,683,312 | December 1, 2019 | November 30, 2025 | EISCHEN, CHRISTINE M. | reporter.nih.gov |
| Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy | NIH | National Cancer Institute | 2021 to 2023 | $1,679,695 | March 15, 2019 | February 28, 2025 | QUERFELD, CHRISTIANE | reporter.nih.gov |
| Mutational cooperativity in TET2-associated hematological malignancies. | NIH | National Cancer Institute | 2021 to 2025 | $1,679,433 | April 1, 2021 | March 31, 2026 | HUANG, YUN | reporter.nih.gov |
| Programmed splicing derangement as new EBV host cell shut-off mechanism | NIH | National Cancer Institute | 2022 to 2025 | $1,676,014 | April 1, 2022 | March 31, 2027 | FLEMINGTON, ERIK K | reporter.nih.gov |
| Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host | NIH | National Cancer Institute | 2021 to 2022 | $1,669,656 | September 2, 2016 | August 31, 2023 | LEVY, RONALD | reporter.nih.gov |
| Optimizing pre-analytic sample handling for high throughput TCR sequencing in cutaneous T cell lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $1,669,583 | September 1, 2020 | May 31, 2026 | CLARK, RACHAEL ANN | reporter.nih.gov |
| Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia | NIH | National Cancer Institute | 2021 to 2024 | $1,669,514 | April 1, 2020 | March 31, 2025 | WANG, LILI | reporter.nih.gov |
| MALT1 as a rational therapeutic target in African American ancestry patients with DLBCL | NIH | National Cancer Institute | 2023 to 2025 | $1,665,977 | September 14, 2023 | August 31, 2028 | ZAPPASODI, ROBERTA | reporter.nih.gov |
| Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy | NIH | National Cancer Institute | 2022 to 2025 | $1,664,746 | April 1, 2005 | December 31, 2026 | RIDDELL, STANLEY R. | reporter.nih.gov |
| In situ atomic structures of the Kaposi's sarcoma-associated herpesvirus portal-terminase complex and glycoproteins | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2024 | $1,663,681 | December 1, 2015 | August 31, 2025 | ZHOU, Z HONG | reporter.nih.gov |
| A Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma Therapy | NIH | National Cancer Institute | 2021 to 2023 | $1,660,806 | August 1, 2019 | July 31, 2024 | ALIZADEH, ASH ARASH | reporter.nih.gov |
| Mechanisms underlying asymmetric rotation and morphogenesis of the midgut | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,655,589 | April 1, 2012 | August 31, 2025 | KURPIOS, NATASZA A | reporter.nih.gov |
| EBV reactivation causes widespread host de novo promoter transcription and transcriptional interference | NIH | National Cancer Institute | 2022 to 2025 | $1,647,874 | July 1, 2022 | June 30, 2027 | FLEMINGTON, ERIK K | reporter.nih.gov |
| Understanding the mechanisms that modulate the effects of mutant Huntingtin lowering in aging Huntington's disease model mice | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,647,634 | February 1, 2022 | January 31, 2027 | ZEITLIN, SCOTT | reporter.nih.gov |
| Epigenetic Mechanisms Underpinning Mantle Cell Lymphoma Sensitivity and Resistance to Notch Inhibitors | NIH | National Cancer Institute | 2022 to 2025 | $1,644,828 | April 1, 2022 | March 31, 2027 | FARYABI, ROBERT BABAK | reporter.nih.gov |
| Elucidating the Mechanisms of Arthritic Flare and Developing Treatments | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $1,629,617 | August 15, 2009 | July 31, 2027 | SCHWARZ, EDWARD M. | reporter.nih.gov |
| Development of a 3D Imaging Diagnostic Tool for the Improved Characterization of Metastatic Melanoma | NIH | National Cancer Institute | 2021 to 2022 | $1,629,519 | May 1, 2021 | April 30, 2023 | VILLANI, THOMAS STEVEN | reporter.nih.gov |
| The Role of Pacs1-Wdr37 inLymphocyte Quiescence and Survival | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,627,700 | February 9, 2022 | January 31, 2027 | NAIR-GILL, EVAN | reporter.nih.gov |
| Novel lymphatic genes that regulate heart valve development and disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,627,457 | December 15, 2022 | November 30, 2026 | SRINIVASAN, RAJANARAYANAN S | reporter.nih.gov |
| The role of lymphatic clearance in brain TB | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,623,071 | May 15, 2022 | April 30, 2027 | SANDOR, MATYAS | reporter.nih.gov |
| Targeting ER stress response in B-cell chronic lymphocytic leukemia | NIH | National Cancer Institute | 2021 to 2025 | $1,620,598 | September 17, 2013 | March 31, 2030 | HU, CHIH-CHI ANDREW | reporter.nih.gov |
| Epigenetic Alterations and Targeted Therapies in North American ATLL | NIH | National Cancer Institute | 2023 to 2025 | $1,618,511 | April 1, 2023 | March 31, 2028 | YE, BIHUI HILDA | reporter.nih.gov |
| KSHV immortalization of human lymphatic endothelial cells | NIH | National Cancer Institute | 2021 to 2025 | $1,615,502 | February 12, 2018 | April 30, 2029 | LAGUNOFF, MICHAEL | reporter.nih.gov |
| Dissecting the Role Ubiquitin E3 Ligase UBR5 in Lymphomagenesis | NIH | National Cancer Institute | 2022 to 2025 | $1,608,284 | August 1, 2021 | July 31, 2026 | BUCKLEY, SHANNON | reporter.nih.gov |
| Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $1,603,351 | September 15, 2022 | June 30, 2027 | DAVIDS, MATTHEW S | reporter.nih.gov |
| Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $1,600,482 | September 1, 2011 | June 30, 2027 | DITTMER, DIRK P | reporter.nih.gov |
| Quantitative analysis of estrogen and sleep deprivation-induced blood and lymphatic vascular remodeling in the brain system | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,596,944 | April 15, 2019 | March 31, 2025 | PALANIAPPAN, KANNAPPAN | reporter.nih.gov |
| Role of KLHL6 inactivation in mature B-cell malignancies | NIH | National Cancer Institute | 2022 to 2025 | $1,596,563 | August 1, 2016 | November 30, 2026 | BUSINO, LUCA | reporter.nih.gov |
| THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESIS | NIH | National Cancer Institute | 2021 to 2025 | $1,578,483 | February 1, 2024 | January 31, 2026 | WILCOX, RYAN A | reporter.nih.gov |
| Pro-resolving lipid mediators in immunity and vascular biology | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,573,911 | August 1, 2011 | June 30, 2025 | SPITE, MATTHEW R | reporter.nih.gov |
| PRODUCTION AND DISTRIBUTION OF FILARIAL RESEARCH REAGENTS DATA | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,573,599 | March 1, 2025 | February 28, 2026 | GUPTA, TUHINA | reporter.nih.gov |
| Defining mechanisms of gammaherpesvirus-driven genomic instability in B cells | NIH | National Cancer Institute | 2022 to 2025 | $1,567,623 | April 4, 2014 | February 28, 2027 | FORREST, JAMES CRAIG | reporter.nih.gov |
| Role of meningeal lymphatic vasculature in neuroimmune communication development | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,566,735 | February 15, 2023 | January 31, 2028 | THOMAS, JEAN-LEON | reporter.nih.gov |
| Effects of EBV Type on Viral Reactivation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,565,574 | May 17, 2019 | April 30, 2025 | KENNEY, SHANNON CELESTE | reporter.nih.gov |
| HIJACKING CANCER DRIVERS TO ACTIVATE PROAPOPTOTIC GENES IN DLBCL | NIH | National Cancer Institute | 2023 to 2025 | $1,563,766 | December 22, 2022 | November 30, 2027 | CRABTREE, GERALD R. | reporter.nih.gov |
| Epiproteomics of Sezary Syndrome | NIH | National Cancer Institute | 2022 to 2024 | $1,560,839 | June 1, 2020 | May 31, 2026 | ELENITOBA-JOHNSON, KOJO S. J. | reporter.nih.gov |
| Erasing ill features of arterial endothelial cells in hereditary hemorrhagic telangiectasia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,560,000 | April 1, 2022 | March 31, 2027 | YAO, YUCHENG | reporter.nih.gov |
| GPCR-mediated pathways for regulation of intestinal lymphatic function | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,552,440 | April 1, 2019 | January 31, 2025 | CARON, KATHLEEN M | reporter.nih.gov |
| Lymphatic Regeneration by Direct Cellular Reprogramming | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,552,332 | July 1, 2023 | June 30, 2027 | YOON, YOUNG-SUP | reporter.nih.gov |
| Dysregulated mechanoimmunology of epigenetics-driven lymphomas | NIH | National Cancer Institute | 2023 to 2025 | $1,542,866 | May 9, 2023 | April 30, 2028 | SINGH, ANKUR | reporter.nih.gov |
| Synovial lymphatics and osteoarthritis in aging | NIH | National Institute on Aging | 2021 to 2024 | $1,542,007 | January 1, 2020 | November 30, 2025 | XING, LIANPING | reporter.nih.gov |
| Meningeal Immunity and Viral Neuropathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,538,230 | August 16, 2024 | July 31, 2029 | DIAMOND, MICHAEL S | reporter.nih.gov |
| Transcriptional Control of Cellular Survival and Proliferation in KSHV-transformed B Cells | NIH | National Cancer Institute | 2021 to 2024 | $1,529,587 | April 13, 2020 | March 31, 2026 | GOTTWEIN, EVA HENRIETTE | reporter.nih.gov |
| Molecular Mechanisms Regulating Neuropilin 2 in Lymphangiogenesis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,529,278 | January 18, 2019 | December 31, 2023 | BIELENBERG, DIANE RENEE | reporter.nih.gov |
| Lymphatic drainage dysfunction in chronic hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,520,151 | July 15, 2024 | May 31, 2028 | BENVENISTE, HELENE D | reporter.nih.gov |
| Therapy Development for Genetic Disorders of the RAS/MAPK Pathway | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,514,750 | May 1, 2024 | March 31, 2028 | GELB, BRUCE D | reporter.nih.gov |
| Intrinsic CSF outflow metrics for mild cognitive impairment and Alzheimer's disease | NIH | National Institute on Aging | 2024 to 2025 | $1,513,078 | May 15, 2024 | January 31, 2029 | MIYAZAKI, MITSUE | reporter.nih.gov |
| Epigenetic Regulation of KSHV Genome Replication | NIH | National Cancer Institute | 2021 to 2023 | $1,505,469 | August 1, 2019 | July 31, 2025 | ROBERTSON, ERLE S. | reporter.nih.gov |
| Role of EBV Lytic Infection in Viral Tumorigenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,505,005 | July 1, 2019 | June 30, 2025 | KENNEY, SHANNON CELESTE | reporter.nih.gov |
| Mechanisms of KSHV-induced endothelial cell loss of contact inhibition of proliferation | NIH | National Cancer Institute | 2023 to 2025 | $1,504,267 | July 1, 2023 | June 30, 2028 | GOTTWEIN, EVA HENRIETTE | reporter.nih.gov |
| Targeting microRNAs in the tumor microenvironment with pHLIP conjugated next generation chemically modified PNAs | NIH | National Cancer Institute | 2021 to 2024 | $1,502,615 | February 15, 2020 | January 31, 2025 | SLACK, FRANK J. | reporter.nih.gov |
| Geospatially modeled environmental risk factors for lymphoid malignancies | NIH | National Institute of Environmental Health Sciences | 2024 to 2025 | $1,500,831 | January 15, 2024 | October 31, 2028 | BIRMANN, BRENDA M | reporter.nih.gov |
| Sleep Promoting Intervention to Improve Diabetes Outcomes and Executive Function in Adolescents with T1D | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,495,974 | March 8, 2024 | February 28, 2029 | JASER, SARAH S | reporter.nih.gov |
| Mechanisms of enhancer regulation in leukemia | NIH | National Cancer Institute | 2021 to 2023 | $1,487,277 | January 1, 2019 | December 31, 2023 | AIFANTIS, IANNIS | reporter.nih.gov |
| Enhancing mitochondrial metabolism to improve anti-tumor CD8 immune response | NIH | National Cancer Institute | 2022 to 2025 | $1,485,537 | March 1, 2022 | February 28, 2027 | RINCON, MERCEDES | reporter.nih.gov |
| Emerging role of glymphatic clearance in Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,482,773 | April 1, 2023 | March 31, 2028 | DUAN, WENZHEN | reporter.nih.gov |
| Langerhans cells and lymphatic regulation in immunity | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $1,480,392 | August 1, 2024 | July 31, 2029 | LU, THERESA T. | reporter.nih.gov |
| Targeting lymph node metastases to block cancer progression | NIH | National Cancer Institute | 2023 to 2025 | $1,472,811 | June 1, 2023 | May 31, 2028 | PADERA, TIMOTHY P | reporter.nih.gov |
| Trpv4 regulation of lymphatic vascular function: Implications in metabolic syndrome | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,468,143 | March 20, 2023 | February 29, 2028 | CASTORENA, JORGE AUGUSTO | reporter.nih.gov |
| mTOR signaling in lung homeostasis, aging and disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,464,620 | May 15, 2020 | April 30, 2025 | KRYMSKAYA, VERA P | reporter.nih.gov |
| Systems Biology of Antigen and T-Cell Transport in Cancer Immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $1,457,022 | July 1, 2023 | June 30, 2028 | PADERA, TIMOTHY P | reporter.nih.gov |
| Mechanisms of STING in malignant progression and therapy of CLL. | NIH | National Cancer Institute | 2023 to 2025 | $1,451,820 | February 1, 2023 | January 31, 2028 | HU, CHIH-CHI ANDREW | reporter.nih.gov |
| Epigenetic Regulation of Epstein-Barr Virus | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $1,451,108 | January 15, 2022 | December 31, 2026 | LIEBERMAN, PAUL M. | reporter.nih.gov |
| RAMP-altered class B GPCR hormone binding and signaling | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,439,860 | September 26, 2012 | August 31, 2025 | PIOSZAK, AUGEN A | reporter.nih.gov |
| Genetic Origins of Adverse Outcomes in African Americans with Lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $1,432,788 | April 18, 2023 | March 31, 2028 | DAVE, SANDEEP | reporter.nih.gov |
| Smoothened as a Novel Signal Stabilization Scaffold in Doxorubicin Resistance | NIH | National Cancer Institute | 2021 to 2023 | $1,431,130 | April 3, 2019 | March 31, 2025 | LANDGRAF, RALF | reporter.nih.gov |
| Synthesis and evaluation of BTN3A1 ligands for cancer immunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $1,423,030 | May 1, 2022 | April 30, 2027 | WIEMER, ANDREW J | reporter.nih.gov |
| Role of EphB4-ephrin-B2 interaction in regulating crosstalk between cancer cell and vascular tumor microenvironment in head and neck cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2023 | $1,422,541 | March 1, 2019 | February 28, 2025 | KARAM, SANA D | reporter.nih.gov |
| Developing novel CAR T cell designs using combinatorial antigen detection | NIH | National Cancer Institute | 2021 to 2025 | $1,421,654 | April 1, 2021 | March 31, 2026 | ALLEN, GREG MANESS | reporter.nih.gov |
| Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation | NIH | National Cancer Institute | 2022 to 2025 | $1,418,567 | August 4, 2016 | March 31, 2027 | GREEN, MICHAEL RICHARD | reporter.nih.gov |
| Chromatin remodeling factor CHD7 regulates cardiac and craniofacial lymphatic vessel development | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,417,874 | July 25, 2024 | April 30, 2028 | LIEN, CHING-LING E | reporter.nih.gov |
| B cell antigen receptor (BCR)-driven mechanistic connection between B cell lymphomagenesis and autoimmunity | NIH | National Cancer Institute | 2021 to 2024 | $1,415,931 | June 1, 2021 | May 31, 2025 | WANG, JING HONG | reporter.nih.gov |
| Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $1,415,907 | August 15, 2022 | June 30, 2027 | RATNER, LEE | reporter.nih.gov |
| Chemokines and Lymphoid Tissue Organization and Function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,409,982 | April 1, 1999 | August 31, 2024 | CYSTER, JASON G | reporter.nih.gov |
| Structure and Function of EBV Protein Complexes that Trigger Epithelial Cell Entry | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,408,573 | February 6, 2018 | January 31, 2024 | LONGNECKER, RICHARD M | reporter.nih.gov |
| Circadian Control of Brain-peripheral Immune Response After Stroke | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,407,466 | August 1, 2023 | July 31, 2028 | ESPOSITO, ELGA | reporter.nih.gov |
| Immune crosstalk through shared LN drainage in the digestive system | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,402,897 | July 1, 2022 | April 30, 2027 | ESTERHAZY, DARIA | reporter.nih.gov |
| Dissecting the functional roles of cardiac lymphatics in ischemic heart disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,401,506 | January 13, 2023 | December 31, 2027 | LIU, XIAOLEI | reporter.nih.gov |
| Dissecting microbiota-driven lymphangiogenesis in immune health and disease | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,401,477 | August 15, 2023 | July 31, 2028 | OVERACRE-DELGOFFE, ABIGAIL E | reporter.nih.gov |
| Genetic pleiotropy across pediatric cancers, and cancer-related outcomes | NIH | National Cancer Institute | 2024 to 2025 | $1,395,864 | May 16, 2024 | April 30, 2029 | WANG, ZHAOMING | reporter.nih.gov |
| Notch and GATA-3 as novel therapeutic targets in T-cell lymphomas | NIH | National Cancer Institute | 2021 to 2024 | $1,395,284 | December 1, 2019 | November 30, 2024 | WILCOX, RYAN A | reporter.nih.gov |
| Identifying Functional Drivers of MYC Activation via Developmental Enhancers in Diffuse Large B-cell Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $1,388,419 | July 1, 2020 | June 30, 2025 | RYAN, RUSSELL JAMES HUBBARD | reporter.nih.gov |
| The role of lymphatics in cholestatic liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,384,487 | September 1, 2024 | June 30, 2026 | IWAKIRI, YASUKO | reporter.nih.gov |
| Developing newly combined therapeutic strategies for mature B cell lymphoma | NIH | National Cancer Institute | 2021 to 2023 | $1,382,659 | April 1, 2021 | March 31, 2024 | WANG, JING HONG | reporter.nih.gov |
| Endothelial cell transplantation for multi-organ repair to counter radiation injury | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,380,785 | April 18, 2018 | March 31, 2025 | RAFII, SHAHIN | reporter.nih.gov |
| Investigating the coordinated endothelial-epithelial interactions in adult hair cycle of mouse skin | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,376,196 | April 28, 2023 | March 31, 2028 | TUMBAR, TUDORITA | reporter.nih.gov |
| Targeting EGR1 signaling pathways in diffuse large B cell lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $1,373,977 | December 20, 2021 | November 30, 2026 | RUI, LIXIN | reporter.nih.gov |
| Drug-Free Macromolecular Therapeutics | NIH | National Cancer Institute | 2021 to 2024 | $1,370,957 | July 1, 2011 | November 30, 2025 | KOPECEK, JINDRICH H. | reporter.nih.gov |
| Impact of Targeted Therapy on Cancer-Related Cognitive Impairment | NIH | National Cancer Institute | 2024 to 2025 | $1,364,661 | September 1, 2024 | August 31, 2029 | GONZALEZ, BRIAN D | reporter.nih.gov |
| Deciphering the Mechanism of Lymphovascular Space Invasion Using a Lymphovascularized Bioengineering Breast Stromal Platform | NIH | National Cancer Institute | 2024 to 2025 | $1,354,247 | June 4, 2024 | May 31, 2026 | RYLANDER, MARISSA NICHOLE | reporter.nih.gov |
| Roles of LMP1 and MYC in EBV-induced B-cell tumors | NIH | National Cancer Institute | 2023 to 2025 | $1,353,918 | September 1, 2023 | August 31, 2028 | KENNEY, SHANNON CELESTE | reporter.nih.gov |
| Lymphatic Support of Neurogenesis and regeneration | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,352,634 | December 1, 2022 | November 30, 2027 | HARRISON, MICHAEL | reporter.nih.gov |
| Targeting delivery of mAbs to CNS metastases | NIH | National Cancer Institute | 2021 to 2024 | $1,345,194 | August 1, 2020 | April 30, 2026 | WEN, JING | reporter.nih.gov |
| AdaptiSPECT-C: A Next-Generation, Adaptive Brain-Imaging SPECT System for Drug Discovery and Clinical Imaging | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $1,341,223 | September 1, 2016 | March 31, 2024 | KING, MICHAEL A | reporter.nih.gov |
| Cardiac lymphatic vessels in heart development and regeneration. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,337,267 | August 28, 2020 | May 31, 2025 | LIEN, CHING-LING E | reporter.nih.gov |
| MSC implantation as a treatment for developmental brain defects in craniosynostosis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,334,824 | June 1, 2024 | May 31, 2029 | CHEN, JIANFU | reporter.nih.gov |
| A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $1,330,000 | August 1, 2024 | July 31, 2027 | VERA, JUAN FERNANDO | reporter.nih.gov |
| Interaction between glymphatic and vascular systems for waste clearance in brain | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $1,328,842 | September 1, 2018 | May 31, 2024 | JIANG, QUAN | reporter.nih.gov |
| Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCT | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,326,660 | August 1, 2019 | June 30, 2023 | VAN DEN BRINK, MARCEL R M | reporter.nih.gov |
| Novel patient biomarkers and mechanisms of TKI associated Cardiotoxicity | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $1,326,247 | August 5, 2023 | April 30, 2028 | ADDISON, DANIEL | reporter.nih.gov |
| Enhancing CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor | NIH | National Cancer Institute | 2021 to 2024 | $1,326,135 | January 1, 2020 | December 31, 2024 | IRVINE, DARRELL J | reporter.nih.gov |
| Next Generation Treatments for Lymphatic Malformations | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,325,071 | March 15, 2024 | February 28, 2029 | STRUB, GRAHAM M | reporter.nih.gov |
| Lymphedema therapy via lymphatic targeted drug delivery | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,322,102 | April 1, 2024 | February 28, 2028 | THOMAS, SUSAN NAPIER | reporter.nih.gov |
| Role of the Lysosome in the Pathogenesis and Therapy of LAM | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,318,383 | July 15, 2020 | June 30, 2025 | HENSKE, ELIZABETH P | reporter.nih.gov |
| Disruption of restorative processes in chronic stress: An integrated cellular approach | NIH | National Center for Complementary & Integrative Health | 2024 to 2025 | $1,318,091 | January 25, 2024 | October 31, 2028 | CIRELLI, CHIARA | reporter.nih.gov |
| Rational Vaccine Design to prevent HIV-Associated Lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $1,312,191 | February 1, 2024 | January 31, 2029 | MCGUIRE, ANDREW | reporter.nih.gov |
| Site-1 protease-mediated lipid metabolism in lymphatic vascular development | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,311,000 | August 1, 2020 | May 31, 2025 | XIA, LIJUN | reporter.nih.gov |
| Define the oncogenic role of METTL3 in the pathogenesis of chronic lymphocytic leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,310,217 | July 1, 2023 | October 30, 2025 | WANG, LILI | reporter.nih.gov |
| Develop lung-targeted synthetic lipid nanoparticles for mRNA medicine treating pulmonary lymphangioleiomyomatosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,305,047 | April 15, 2024 | February 29, 2028 | XU, QIAOBING | reporter.nih.gov |
| Genetic Analysis of Myeloproliferative Disease | NIH | National Cancer Institute | 2021 to 2024 | $1,293,659 | April 1, 1999 | February 28, 2026 | COWELL, JOHN K | reporter.nih.gov |
| Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,292,812 | July 15, 2023 | June 30, 2028 | SWAMINATHAN, SRIVIDYA | reporter.nih.gov |
| Targeting EBV-associated lymphomas | NIH | National Cancer Institute | 2024 to 2025 | $1,290,024 | September 10, 2024 | August 31, 2029 | DAMANIA, BLOSSOM A | reporter.nih.gov |
| Resolving Spatiotemporal Dynamics of Recombinant Poliovirus Immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $1,289,448 | July 28, 2023 | June 30, 2028 | GROMEIER, MATTHIAS | reporter.nih.gov |
| Pathways Regulating Lymphatic Vessel Permeability and Valve Formation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,287,720 | May 24, 2019 | April 30, 2025 | SCALLAN, JOSHUA PAUL | reporter.nih.gov |
| CRCNS: Waste-clearance flows in the brain measured using physics-informed neural network | NIH | National Center for Complementary & Integrative Health | 2022 to 2025 | $1,284,101 | September 19, 2022 | June 30, 2027 | KELLEY, DOUGLAS H | reporter.nih.gov |
| Identifying Multi-Level Predictors and Outcomes of Oral Anticancer Medication Adherence Initiation and Persistence among Patients with Hematologic Malignancies | NIH | National Cancer Institute | 2024 to 2025 | $1,283,191 | August 1, 2024 | July 31, 2029 | BELCHER, SARAH M. | reporter.nih.gov |
| The Role of Tie1 in Gut and Mesenteric Lymphatic Function | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,281,398 | June 15, 2020 | April 30, 2025 | BALDWIN, H SCOTT | reporter.nih.gov |
| Notch ligands as oncogenic drivers and therapeutic targets in T-cell lymphomas | NIH | National Cancer Institute | 2024 to 2025 | $1,277,693 | January 1, 2024 | December 31, 2028 | WILCOX, RYAN A | reporter.nih.gov |
| Systemic Enzyme Delivery by a Brain Targeted SapC-DOPS Nanocarrier for Treatment of Neuronopathic Gaucher Disease | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,276,590 | July 1, 2024 | June 30, 2029 | SUN, YING | reporter.nih.gov |
| CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma | NIH | National Cancer Institute | 2021 to 2023 | $1,275,832 | August 1, 2021 | March 1, 2024 | WANG, ZHIRUI | reporter.nih.gov |
| Replication stress in hematopoiesis and lymphomagenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,266,867 | December 1, 2018 | November 30, 2025 | EISCHEN, CHRISTINE M. | reporter.nih.gov |
| NanoOptogenetic immunotherapy for B cell lymphoma | NIH | National Cancer Institute | 2021 to 2023 | $1,264,108 | May 1, 2019 | April 30, 2025 | HAN, GANG | reporter.nih.gov |
| Oxidized LDL dependent reprogramming of the liver lymphatic endothelium | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,263,231 | June 1, 2020 | March 31, 2025 | BURCHILL, MATTHEW A | reporter.nih.gov |
| Comprehensive Molecular and Clinical Characterization of Acute and Chronic Neurotoxicity Following CAR-T Cell Therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,262,391 | September 15, 2024 | August 31, 2029 | SANTOMASSO, BIANCA DENISE | reporter.nih.gov |
| A novel approach to delivering therapeutics in heart transplantation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,255,235 | September 1, 2019 | December 31, 2022 | ABDI, REZA | reporter.nih.gov |
| PET/CT Imaging of Venous Thromboembolism in Pediatric, Adolescent, and Young Adult Oncology | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,254,556 | July 15, 2024 | May 31, 2029 | STACY, MITCHEL R | reporter.nih.gov |
| Defining the Role of Post-TBI Sleep Disruption in the Development of CTE and Alzheimer's Disease-Related Neuropathology | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $1,253,356 | September 20, 2022 | August 31, 2027 | PESKIND, ELAINE R. | reporter.nih.gov |
| Adrenomedullin Signaling at the Maternal-Fetal Interface | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $1,252,975 | April 1, 2009 | January 31, 2028 | CARON, KATHLEEN M | reporter.nih.gov |
| Targeting Wnt signaling pathway | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,251,430 | April 1, 2023 | March 31, 2027 | CAI, JIANFENG | reporter.nih.gov |
| GM3 Nanoparticles for Sustained Delivery of Anti-Retrovirals to Lymphatic Tissues | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,250,596 | November 8, 2017 | October 31, 2023 | GUMMULURU, SURYARAM | reporter.nih.gov |
| Stringent Latent Epstein-Barr Virus (EBV) Infection Collaborates with Cellular Gene Alterations to Induce EBV+ Lymphomas | NIH | National Cancer Institute | 2023 to 2025 | $1,247,765 | July 1, 2023 | June 30, 2028 | KENNEY, SHANNON CELESTE | reporter.nih.gov |
| A Next-Generation Nucleoside Prodrug for Diffuse Large B-Cell Lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $1,247,192 | December 18, 2023 | November 30, 2028 | POMERANTZ, RICHARD T | reporter.nih.gov |
| Mapping the perivascular reticular network in health, aging, and AD | NIH | National Institute on Aging | 2023 | $1,246,362 | September 1, 2023 | August 31, 2026 | MEHTA, RUPAL I. | reporter.nih.gov |
| Peripheral Nerve Regulation of Pancreas Cancer Progression | NIH | National Cancer Institute | 2024 to 2025 | $1,245,096 | July 1, 2024 | June 30, 2029 | SALOMAN, JAMI LYNN | reporter.nih.gov |
| The role of ATM in the suppression of lymphoid malignancy | NIH | National Cancer Institute | 2021 to 2025 | $1,239,512 | March 1, 2011 | July 31, 2029 | ZHA, SHAN | reporter.nih.gov |
| Novel enhancement of antibody therapy through NOD2 activation | NIH | National Cancer Institute | 2024 to 2025 | $1,236,215 | September 1, 2024 | August 31, 2029 | TRIDANDAPANI, SUSHEELA | reporter.nih.gov |
| Retinoic Acid Induced Lymphangiogenesis for Post-Surgical Lymphedema | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,232,103 | September 1, 2021 | August 31, 2027 | WONG, ALEX K. | reporter.nih.gov |
| Clinical and Genetic Origins of Monomorphic Epitheliotropic Intestinal T Cell Lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $1,228,976 | January 1, 2023 | December 31, 2027 | DAVE, SANDEEP | reporter.nih.gov |
| USP7 targeting by HHV-8 vIRFs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,228,125 | March 1, 2019 | February 28, 2025 | NICHOLAS, JOHN | reporter.nih.gov |
| Characterization of Diverse Pediatric Cancers in LMIC Using Low-Cost Nanopore Sequencing | NIH | National Cancer Institute | 2024 to 2025 | $1,226,342 | July 15, 2024 | June 30, 2026 | WANG, JEREMY R | reporter.nih.gov |
| Methods and Tools for Integrating Pathomics Data into Cancer Registries | NIH | National Cancer Institute | 2021 to 2022 | $1,223,841 | April 1, 2018 | March 31, 2024 | SALTZ, JOEL H. | reporter.nih.gov |
| TissueReM: Whole-Organism, Real-time Decision-enabled 3D Tissue Imaging and Recovery for Molecular Analysis | NIH | National Institute of General Medical Sciences | 2025 | $1,221,189 | August 5, 2022 | July 31, 2027 | GARGESHA, MADHUSUDHANA | reporter.nih.gov |
| Lymphothrombosis in gut health and disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,218,750 | September 15, 2019 | June 30, 2024 | KAHN, MARK L | reporter.nih.gov |
| Characterizing stem cell-like B cell subpopulations and dissecting their role in tumorigenesis | NIH | National Cancer Institute | 2023 to 2025 | $1,207,701 | July 1, 2023 | June 30, 2028 | APOSTOLOU, EFFIE | reporter.nih.gov |
| Restriction of KSHV by cellular RNA decay pathways | NIH | National Cancer Institute | 2023 to 2025 | $1,200,939 | April 1, 2023 | March 31, 2028 | KARIJOLICH, JOHN | reporter.nih.gov |
| Developing novel therapy to improve outcomes in MCL | NIH | National Cancer Institute | 2023 to 2025 | $1,200,590 | July 12, 2023 | June 30, 2028 | SEHGAL, LALIT | reporter.nih.gov |
| PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $1,199,248 | August 2, 2017 | July 31, 2023 | LIN, YI | reporter.nih.gov |
| Decoupling acute toxicities and antitumor efficacy in adoptive cell therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,194,123 | May 1, 2024 | April 30, 2029 | LU, YONG | reporter.nih.gov |
| Supporting WHO Lymphatic Filariasis Elimination Programs: Progressing a Highly Sensitive and Specific Rapid Diagnostic Test for Brugia Species Infection to Commercialization Readiness | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,193,706 | May 1, 2024 | April 30, 2027 | BIAMONTE, MARCO ANTONIO | reporter.nih.gov |
| Role of the GI lymphatic system in hormonal signaling and nutrient metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,187,887 | September 20, 2018 | May 31, 2024 | LIU, MIN | reporter.nih.gov |
| Tissue-Engineered Models of Lymphatic Drainage in Breast Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,182,836 | June 23, 2023 | May 31, 2028 | LEE, ESAK | reporter.nih.gov |
| Sexual dimorphism and the immuno-modulatory role of estrogen signaling in HNSCC | NIH | National Cancer Institute | 2024 to 2025 | $1,182,033 | July 3, 2023 | June 30, 2028 | KARAM, SANA D | reporter.nih.gov |
| R-loop-induced DNA damage during immunoglobulin class switch recombination | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,174,235 | August 5, 2019 | July 31, 2025 | BARLOW, JACQUELINE | reporter.nih.gov |
| Functional genetics of human innate immunity in the bimodal gamma delta T cell response to Epstein-Barr Virus and in education of NK cells and their re-education to respond to autologous cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,173,750 | February 5, 2019 | July 31, 2024 | PARHAM, PETER R | reporter.nih.gov |
| Modeling cancer risk and environmental and socio-spatial exposures using residential histories | NIH | National Cancer Institute | 2021 to 2024 | $1,173,164 | April 1, 2021 | March 31, 2026 | SABO, ROY TRAVIS | reporter.nih.gov |
| Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH) | NIH | National Cancer Institute | 2023 to 2024 | $1,169,589 | September 1, 2023 | October 1, 2024 | DHARNIDHARKA, VIKAS R. | reporter.nih.gov |
| Direct chemical control of the hematopoietic master transcription factor PU.1 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,169,375 | January 1, 2021 | December 31, 2025 | POON, GREGORY MAN KAI | reporter.nih.gov |
| The Role of Follicular CD8+ T Cells in Pathogenesis of AIDS-NHL. | NIH | National Cancer Institute | 2021 to 2023 | $1,168,002 | August 9, 2019 | July 31, 2025 | EPELDEGUI, MARTA | reporter.nih.gov |
| Imaging cerebral waste clearance responses during exosome treatment of diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,164,662 | April 15, 2024 | March 31, 2029 | JIANG, QUAN | reporter.nih.gov |
| Role of E3 Ligase UBR5 in Alternative Splicing during B Cell Development and Activation | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,158,775 | August 25, 2021 | July 31, 2025 | BUCKLEY, SHANNON | reporter.nih.gov |
| Immunological and functional consequences triggered by the gut microbiota regulate alloimmunity and cardiac transplant outcome | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,157,468 | July 15, 2019 | June 30, 2024 | BROMBERG, JONATHAN S | reporter.nih.gov |
| Investigating T Cell Egress via Lymphatic Vessels in Melanoma | NIH | National Cancer Institute | 2021 to 2023 | $1,155,439 | March 1, 2020 | February 28, 2025 | LUND, AMANDA W. | reporter.nih.gov |
| Regulation of lymphatic muscle cell function by store operated calcium entry signaling | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,153,370 | August 1, 2024 | June 30, 2029 | ZAWIEJA, SCOTT D. | reporter.nih.gov |
| Metabolic control of human endothelial development via the COUP-TF/1-deoxysphingosine axis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,152,693 | May 1, 2024 | March 31, 2028 | IVANOVA, NATALIA B | reporter.nih.gov |
| Role of Rasa1 in embryonic development | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $1,151,928 | September 1, 2024 | May 31, 2029 | LAWSON, NATHAN D | reporter.nih.gov |
| A Single-Cell Proteomic instrument for Predictive Product Quality Check in Autologous CAR-T Immunotherapies | NIH | National Cancer Institute | 2021 | $1,150,207 | September 21, 2016 | May 31, 2022 | ZHOU, JING | reporter.nih.gov |
| Imaging small blood and lymphatic vessel abnormalities of the olfactory system in schizophrenia | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $1,147,699 | September 1, 2018 | May 31, 2024 | HUA, JUN | reporter.nih.gov |
| Multimodal Learning for Contextually-Aware Longitudinal PET/CT image analysis | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $1,141,556 | December 1, 2023 | November 30, 2027 | BRADSHAW, TYLER J | reporter.nih.gov |
| Targeting IKKepsilon-mediated nucleotide synthesis in KSHV-associated lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $1,138,031 | July 1, 2023 | June 30, 2028 | FENG, PINGHUI | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Weill Medical Coll of Cornell Univ | New York, NY | 36 | $54.6 million | 0 | $0 |
| Ohio State University | Columbus, OH | 21 | $48.7 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 19 | $44.5 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 34 | $41.5 million | 0 | $0 |
| Yale University | New Haven, CT | 26 | $41.5 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 18 | $39.2 million | 0 | $0 |
| Washington University | Saint Louis, MO | 28 | $38.4 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 29 | $38 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 37 | $36.2 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 21 | $29.8 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 23 | $27 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 27 | $26.6 million | 0 | $0 |
| Stanford University | Stanford, CA | 27 | $26.4 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 24 | $25.4 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 18 | $24.6 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 23 | $23.2 million | 0 | $0 |
| Midwest Research Institute | Kansas City, MO | 1 | $22.6 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 25 | $22.5 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 12 | $19.6 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 15 | $19.5 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 10 | $17.4 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 10 | $17 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 17 | $17 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 15 | $16.5 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 13 | $15.1 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 12 | $14.7 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 14 | $13.9 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 9 | $13.8 million | 0 | $0 |
| Duke University | Durham, NC | 14 | $13.8 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 9 | $13.4 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 14 | $13.3 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 11 | $12.5 million | 0 | $0 |
| University of Rochester | Rochester, NY | 11 | $12.5 million | 0 | $0 |
| Cornell University | Ithaca, NY | 12 | $12.3 million | 0 | $0 |
| H. Lee Moffitt Cancer CTR & Res Inst | Tampa, FL | 7 | $12.1 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 7 | $11.5 million | 0 | $0 |
| University of Florida | Gainesville, FL | 15 | $11.5 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 10 | $11.2 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 17 | $11 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 7 | $10.9 million | 0 | $0 |
| University of South Florida | Tampa, FL | 10 | $10.8 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 12 | $10.7 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 12 | $10.6 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 10 | $10.4 million | 0 | $0 |
| Oklahoma Medical Research Foundation | Oklahoma City, OK | 6 | $10.3 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 8 | $9.9 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 8 | $9.8 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 8 | $9.2 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 5 | $9 million | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 9 | $9 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 5 | $8.2 million | 0 | $0 |
| Seattle Inst for Biomedical/clinical Res | Seattle, WA | 5 | $8.2 million | 0 | $0 |
| University of Washington | Seattle, WA | 10 | $8.2 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 6 | $8.2 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 8 | $8 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 7 | $7.9 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 10 | $7.9 million | 0 | $0 |
| University of Chicago | Chicago, IL | 9 | $7.7 million | 0 | $0 |
| Palo Alto Veterans Instit for Research | Palo Alto, CA | 5 | $7.7 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 5 | $6.8 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 6 | $6.4 million | 0 | $0 |
| Boston Immune Technologies and Therapeutics, Inc. | Winchester, MA | 1 | $6.4 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 6 | $6.3 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 9 | $6.1 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 6 | $6 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 6 | $5.9 million | 0 | $0 |
| Rush University Medical Center | Chicago, IL | 6 | $5.9 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 6 | $5.7 million | 0 | $0 |
| Hugo W. Moser Res Inst Kennedy Krieger | Baltimore, MD | 3 | $5.7 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 3 | $5.5 million | 0 | $0 |
| Emory University | Atlanta, GA | 12 | $5.4 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 5 | $5.3 million | 0 | $0 |
| University of Texas at Austin | Austin, TX | 4 | $5.2 million | 0 | $0 |
| Univ of Arkansas for Med Scis | Little Rock, AR | 9 | $5.1 million | 0 | $0 |
| Rockefeller University | New York, NY | 4 | $5.1 million | 0 | $0 |
| University of California at Davis | Davis, CA | 8 | $5 million | 0 | $0 |
| Texas A&m University Health Science CTR | College Station, TX | 5 | $4.9 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 6 | $4.8 million | 0 | $0 |
| Broad Institute, Inc. | Cambridge, MA | 4 | $4.7 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 3 | $4.6 million | 0 | $0 |
| Research Inst of Fox Chase Can CTR | Philadelphia, PA | 3 | $4.6 million | 0 | $0 |
| Feinstein Institute for Medical Research | Manhasset, NY | 3 | $4.6 million | 0 | $0 |
| Hospital for Special Surgery | New York, NY | 3 | $4.6 million | 0 | $0 |
| Mayo Clinic Jacksonville | Jacksonville, FL | 3 | $4.5 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 3 | $4.3 million | 0 | $0 |
| Henry Ford Health + Michigan State University Health Sciences | East Lansing, MI | 2 | $4.2 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 7 | $4.1 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 4 | $4.1 million | 0 | $0 |
| University of California-Riverside | Riverside, CA | 3 | $4.1 million | 0 | $0 |
| Children's Hospital of Los Angeles | Los Angeles, CA | 3 | $3.7 million | 0 | $0 |
| Boston College | Chestnut Hill, MA | 1 | $3.6 million | 0 | $0 |
| Tufts Medical Center | Boston, MA | 2 | $3.5 million | 0 | $0 |
| Pai Life Sciences, Inc. | Seattle, WA | 1 | $3.4 million | 0 | $0 |
| Avm Biotechnology, LLC | Seattle, WA | 3 | $3.4 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 5 | $3.4 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 5 | $3.3 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 6 | $3.3 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 2 | $3.2 million | 0 | $0 |
| Big Eye Diagnostics, Inc. | San Diego, CA | 2 | $3.1 million | 0 | $0 |
| March Biosciences INC | Houston, TX | 2 | $3.1 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 603 | $328,511,582 | 0 | $0 |
| 2024 | 612 | $294,207,878 | 0 | $0 |
| 2023 | 634 | $296,996,656 | 0 | $0 |
| 2022 | 628 | $275,859,666 | 0 | $0 |
| 2021 | 553 | $245,129,841 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.